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resumo 
 
 
O presente documento descreve o estágio curricular realizado na clínica 
Lenitudes Medical Center & Research, localizada em Santa Maria da Feira, 
que decorreu desde 1 de setembro de 2015 até 31 de maio de 2016. Este 
estágio foi realizado no âmbito do segundo ano do Mestrado em Biomedicina 
Farmacêutica da Universidade de Aveiro e teve como objetivos a aquisição de 
competências técnicas, experiência e consolidação de conhecimentos nas 
áreas de Gestão de Risco e Farmacovigilância. Para além da aquisição de 
conhecimentos teóricos, este período de estágio foi fundamental para o 
desenvolvimento de um conjunto de aptidões sociais e pessoais que 
contribuíram para o meu crescimento profissional dentro da instituição de 
acolhimento.  
 
O estágio focou essencialmente tópicos relacionados com a Gestão de Risco, 
envolvendo a elaboração do Manual de Gestão de Risco da unidade, bem 
como relatórios periódicos de monitorização de eventos adversos associados à 
radioterapia. Adicionalmente, durante o estágio foram realizadas atividades de 
carácter multidisciplinar relacionadas com processos iniciais de investigação e 
medical writing. 
 
Esta foi uma experiência bastante enriquecedora, de grande valor a nível 
profissional, pessoal e social, que me permitiu atingir os principais objetivos 
estabelecidos. 
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abstract 
 
This document describes an internship carried out in the healthcare unit 
Lenitudes Medical Center & Research, located in Santa Maria da Feira, held 
from 1st September 2015 until 31st May 2016. This internship was performed as 
part of the second year of the Master in Pharmaceutical Biomedicine at the 
University of Aveiro, aiming to acquire technical skills and experience in Risk 
Management and Pharmacovigilance, as well as to consolidate previous 
knowledge. Besides the acquisition of theoretical knowledge, this training 
period was paramount for the development of a number of social and personal 
skills that contributed for my profissional growth within the host institution. 
 
The training mainly focused in topics related to Risk Management, involving the 
preparation of the Risk Management Manual of the unit and adverse events 
monitoring periodic reports associated with radiotherapy. Additionally, during 
the internship were conducted multidisciplinary activities related to initial 
processes regarding research and medical writing. 
 
This internship was a very enriching experience with great value on a 
professional, personal and social level, that allowed me to achieve the main 
objectives established. 
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1.!Introduction 
The present document constitutes a report about my curricular internship within the 
scope of the Master’s Degree in Pharmaceutical Biomedicine of University of Aveiro. This 
internship was performed in Lenitudes Medical Center & Research (Lenitudes MC&R), in 
Santa Maria da Feira, and started in September 1st 2015 and ended in May 31st 2016.  
The activities developed during the internship, as well as the learning outcomes and 
skills acquired during this period, were related to risk management and pharmacovigilance, 
including a proposal for the creation of tools for reporting of Adverse Events (AE) associated 
with clinical practice. Nevertheless, were also carried out activities in other areas such as 
quality management, through the collaboration in the development of Standard Operating 
Procedures (SOPs), project management, medical writing and other tasks related to clinical 
research. 
 
1.1!Objectives 
The objectives for this on-the-job experience at Lenitudes MC&R were defined in the 
beginning of the internship and divided into three main areas described below: 
!! The goals required to conclude the master’s degree: 
!! To improve the knowledge and skills in Pharmacovigilance and Risk 
Management; 
!! To acquire knowledge about the procedures to increase patient safety, by 
developing tools for reporting of AE associated with chemotherapy and 
radiotherapy treatment; 
!! To collaborate in SOPs’ developing; 
!! To be familiarized with national and international regulatory legislation 
applicable to pharmacovigilance and risk management in healthcare units; 
!! To know the International Organization for Standardization (ISO) standards 
applicable to risk management; 
!! To face the healthcare market and the reality within a healthcare unity. 
!! The objectives related to collaboration on the projects and work within the host 
company: 
!! To be integrated within the clinic’s projects; 
!! To collaborate on documentation organization and record; 
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!! To get knowledge about the different types of incidents which can occur in 
a clinical unit with the Lenitudes MC&R’s characteristics; 
!! To observe how communication flows throughout the various sectors within 
a healthcare unity. 
!! The aims associated to my personal development: 
!! To contact with the clinical environment and adapt to professional life; 
!! To understand the applicability of the knowledge and skills developed 
during academic training; 
!! To recognize my difficulties and strengths and improve them; 
!! To develop personal and professional skills, such as time management, 
communication skills (verbal and written), responsibility, autonomy, critical 
thinking and problem solving. 
 
1.2!Host Organization Portrait 
As mentioned above, my curricular internship occurred in a subunit of Lenitudes SGPS 
company – Lenitudes MC&R. Lenitudes SGPS is a holding company located in Lisbon, 
which comprises the administration department, general management, project 
management and legal support of other companies related to health services. Lenitudes 
SGPS embraces the following units (figure 1 and 2) (1): 
!! Lenicare – a radiotherapy unit located in Évora, constituting a public-private 
partnership between the Lenitudes and Hospital Espírito Santo; 
!! Lenitudes MC&R – my host company, that started being constructed right after 
Lenicare, in Santa Maria da Feira; 
!! HPP Molecular Medicine unit (Porto);  
!! LMN Nuclear Medicine (Braga) 
!! Surgical hospital (Setúbal) and Hospital (Portimão) – units which will be 
developed after Lenitudes in Santa Maria da Feira has opened and started 
operating.  
Lenitudes SGPS, SA Lisboa
Lenicare Lenitudes 
MC&R
HPP-MM 
(Porto) LMN-Braga
Surgical 
hospital
(Setúbal)
Hospital 
(Portimão)
Figure 1 - Lenitudes SGPS Representation and its clinical units (1) 
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Figure 2 - Lenitudes units’ location (1) 
 
 
1.2.1! Lenitudes MC&R 
The Lenitudes MC&R is a healthcare unit, with focus on the treatment of cancer, which 
belongs to Lenitudes’ group, being administered by some members of this holding 
company. Prof. Francisco Pimentel, my training supervisor, is responsible for Lenitudes 
MC&R’s clinical leadership.  
The internal structure of the company is represented in figure 3 (1). In December 2015, 
the Lenitudes’ structure was expanded with the acquisition of HPP Nuclear Medicine unit 
(Porto) and LMN-Braga, enhancing its resources and its operation area. HPP Nuclear 
Medicine Units are operating since 12 years ago, having a high number of patients, 
providing the following diagnostic and therapeutic exams (1): 
!! Gallium scintigraphy; 
!! Cerebral perfusion scintigraphy; 
!! Myocardial perfusion scintigraphy; 
!! Bone scintigraphy; 
!! Scintigraphy lung ventilation / perfusion; 
Lenitudes SGPS, SA 
HPP – Molecular Medicine (Porto) 
 
Lenicare 
LMN - Braga 
 
Surgical hospital 
(Setúbal) 
Hospital (Portimão) 
Lenitudes MC&R 
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!! Renal scintigraphy; 
!! Thyroid scintigraphy; 
!! Positron Emission Tomography (PET) or PET/Computerized Tomography 
(PET/CT); 
!! Single Photon Emission Computed Tomography (SPECT); 
!! Brain SPECT with Ceretec™ or Neurolite™; 
!! Brain SPECT imaging with DaTSCAN; 
!! Therapeutic Iodine - 131 with patient admission. 
Beyond this, there are some services that are performed by outsourced companies, 
such as: 
!! Human resources for radiotherapy (except specialist physicians); 
!! Cleaning and hygiene; 
!! The laundry and the waste management services; 
!! The sterilization of the surgical and medical instruments and devices. 
The activities developed during my internship may be included in the Quality/Risk 
Management department (represented in figure 3 in red color), which is transverse to 
Lenitudes SGPS company. Additionally, I also performed some Research and Development 
(R&D) activities in the area of project management and medical writing (also represented 
in figure 3 in red color). 
 
This healthcare facility located in Santa Maria da Feira (figure 4) provides a range of 
clinical services that extend from the diagnostic techniques to clinical treatments. The center 
has several medical offices and nursing rooms, chemotherapy and preparation of 
cytostatics rooms, surgical and recovery rooms, research laboratories, radiotherapy rooms, 
imaging and nuclear medicine. Figure 5 is a sketch of the Lenitudes, with the areas and 
services it has to offer: 
!! Nuclear medicine – with two different equipment from General Eletrics, new PET/CT 
– Discovery IQ ® – and one gamma camera SPECT – Discovery NM360 ® –, 
Lenitudes MC&R has the ultimate technology. The equipment PET/CT is only 
available in few places worldwide, offering a better image in less time with a much 
lower dose of radio drugs. 
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 Figure 3 -  Lenitudes MC&R organisation chart’s proposal (2) 
Lenitudes)SGPS,)SA
Lisboa
Technical)support)
groups
Oncological)
Coordination)
Commission
Ethics)Committee
Pharmacy)and)
Therapeutics)
Commission
Hospitalar)Infections)
Control)Commission
Quality)Management
Risk)Management
Lenitudes)MC&R
Admnistration)Council
Clinical)Leadership:)
Professor)Francisco)
Pimentel
Clinical
Medical)Specialtities)
Oncology
Radiotherapy
Nuclear)Medicine
Imagiology
Surgery
Nursing
Superior)Technicians
Pharmacy)
Sterilisation
Laboratories)(Clinical)
pathology,)Patologic)
Anatolmy)and)
Imunohemotherapy)
R&D
Clinical)Research
Coordination
Data)Management
Project)Management
Medical)Writing
Management
Secretary
Human)Resources
Financial
General)Management
Morgue
Provision)and)Supplies
Equipment)
Maintenance
Hygiene)and)Cleaning
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Figure 4 – Lenitudes MC&R’s building image (1) 
 
!! Imaging – includes echography, radiology and mammography, with special attention 
for two echo graphs (LOGIQ C5® and LOGIQ E9 XdClear®), one mammography 
(Senographe Essential®), one ultimate model of echocardiograph (VIVID E9 
XdClear®) and the surgery X-Ray arch C (Brivo Essential®), that constitute also 
cutting-edge devices; 
!! Radiotherapy – Lenitudes MC&R offers a more precise treatment, since the two 
Elekta accelerators produce a more accurate radiation beam, in a fewer time, 
causing less collateral damage. In this way, the healthy cells located near the tumour 
will hardly be affected; 
!! Outpatient surgery – the unit has the two surgical rooms equipped with high 
technology, which will be used by multidisciplinary surgical teams, plus three 
recovery areas (including four bedrooms). In future, the professionals will use 
advanced surgical techniques, and even irreversible electroporation procedures; 
!! Chemotherapy (medical oncology) – with four individual rooms and one larger room 
for four patients;  
!! Clinic consultations, including several medical specialties: psychology and nutrition, 
gynaecology/urology, otorhinolaryngology, neurology, gastroenterology, 
anaesthesiology and pain, orthopaedic, psychiatry, dermatology, radiotherapy, 
nuclear medicine, cardiology, pulmonology and medical oncology;  
!! R&D – within two laboratories, one for basic research and other for clinical research;  
!! Palliative care and partnerships with other clinical centres. 
Although Lenitudes MC&R unit intends to focus on cancer patients, it presents more 
valences which expand its activity. The nuclear medicine devices can be used for 
diagnosing other diseases, consulting rooms are intended to multiple medical specialties 
and it is also possible to perform surgical procedures for other pathologies beyond cancer. 
This clinic aims to go further, offering sleep studies, clinical trials, neurological research 
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related to nuclear medicine techniques. The management and clinical evaluation of the 
results of each treatment will allow the unit to provide a more personalized treatment for 
each patient. In conclusion, the Lenitudes MC&R is very committed to offer quality services, 
keeping in mind its continuous improvement, ensuring the satisfaction of the expectations 
and needs of the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5 - Lenitudes MC&R's map  drawing (1 - Reception, 2 - Consultation/Examination rooms, 3 - Nuclear 
Medicine and Molecular Imaging, 4 - Imagiology, 5 - Radiotherapy, 6 - Surgery, 7 - Day Hospital, 8 - 
Administration and Research & Development) (1) 
2 
1 
3 4 56 
7 8 
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1.3!Reports’ Structure 
This report is structured in order to, in this section, provide a brief overview of the 
institution, as well as the proposed objectives for my internship. This chapter is followed by 
a general framework on safety in health care, the impact of AE and the importance of 
surveillance and reporting. Then risk management is introduced, identifying the main 
methods and clarifying its fundamental importance to the company in question. 
In the following chapters, the multidisciplinary experience and all the activities that I 
have participated during this period will be described. A brief discussion and conclusion will 
be presented at the end, displaying my personal opinion, the main obstacles faced during 
this period, as well as the skills acquired, learning outcomes achieved and its importance 
to my personal, interpersonal and professional growth. 
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2.!General Framework 
Health facilities have the main mission of providing their patients a range of services 
with high quality and efficiency, based on the best evidence available, free of damage and 
risks, ensuring the satisfaction and personal safety of individuals (3). However, as in any 
other area, there is always a chance of failure and a risk inherent in the professional practice 
(3,4). Failures resulting from health care have a direct implication on patients and inevitably 
compromise the main mission defended. Because of the impact caused, either on patient 
or in health facilities, in the last two decades the subject of security in health care has 
become a central issue for the scientific community from many countries of Europe and the 
world, constituting an essential area of health quality (3–5). 
According to Conceptual Framework for the International Classification for Patient 
Safety (ICPS), published in 2009 by the World Health Organization (WHO) and by the 
Health Direction (Direção-Geral da Saúde – DGS in Portuguese) in 2011, patient safety can 
be defined as "the reduction of the risk of unnecessary harm associated to health care, to 
an acceptable minimum”1 (6). As it is accepted that the risk is a constant in health care, it is 
also assumed that it is impossible to eliminate it completely, being a minimum level 
accepted. This level of residual risk is weight taking into account the current knowledge in 
the area, the resources available and the context in which care is provided, compared to 
the risk of an alternative treatment or even with the patient's risk of not being subject to no 
treatment (3,6). Errors are considered failures in carrying out a planned action in 
accordance with the provisions or the incorrect development of a plan (6). These faults have 
unintended nature and can manifest through the practice of a wrong action or are unable to 
perform the correct action, either in its planning or execution (3,6). When a change occurs 
in a procedure, in a deliberate and intentional way, this deviation is not considered an error, 
but a violation (6). Both errors and violations increase the risk to the patient and, 
consequently, added the probability of an incident. According to the ICPS, an incident is 
usually unexpected and undesirable occurrence, which may have led, or actually led to 
unintended damage and/or unnecessary for the patient (6). In this same document, the 
incidents are classified into 13 different types including (6): 
1.! Clinical administration; 
2.! Clinical process/procedure; 
 
1 In portuguese definition: “segurança do doente é a redução do risco de danos desnecessários relacionados com os cuidados 
de saúde, para um mínimo aceitável”. 
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3.! Documentation; 
4.! Healthcare associated infection; 
5.! Medication/intravenous fluids; 
6.! Blood/blood products; 
7.! Nutrition; 
8.! Oxygen/gas/vapour; 
9.! Medical devices/equipment; 
10.! Behavior; 
11.! Patient accidents; 
12.! Infrastructure/buildings/fixtures; 
13.! Resources/organizational management.  
 
In addition to its type, depending on the attributes which it presents, an incident can 
be a reportable circumstance, near miss, no harm incident or harmful incident/AE  
(Table 1) (6). 
 Table 1 - Class attributes of patient safety incidents (6) 
 
The AE represent the class of incidents with greatest concern, since in these 
situations, damage caused in the course of care, rather than the underlying disease, results 
in measurable disability for the patient. These incidents are therapeutic adversity, iatrogenic 
damage or other events caused by complications with drugs, medical devices, infected 
wounds, complications caused by neglect, misdiagnosis, maladjusted therapies, etc. (6). 
We are facing an Adverse Drug Event (ADE) when any unfavorable and unintended 
occurrence happens after using a drug, regardless of the existence of a causal link between 
the AE and the administration or taking the medication (6–8). This event is only considered 
Reportable 
circumstance 
A situation in which there was significant potential for harm, but 
no incident occurred. 
Almost event 
(near miss) An incident which did not reach the patient. 
No harm incident An incident which reached a patient but no discernable harm resulted. 
Harmful incident 
(AE) 
An incident involving harm to the structure or function of the 
body and/or any deleterious resulting effect (illness, injury, 
suffering, disability or death). 
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as an Adverse Drug Reaction (ADR) if it is actually proven that the drug was responsible 
for the unwanted occurrence, that is, whenever there is actually a possible causal link 
between the occurrence of the AE and the use of the product (figure 6). This includes all 
situations resulting from the use of a drug according to the marketing authorization as well 
as those that occur in a use that is not in as described in the Summary of Product 
Characteristics (SmPC) and the Package Leaflet (PL), including those resulting from 
medication errors, misuse, abuse or resulting from occupational exposure to drug (6–8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When damage occurs to the patient is extremely important to identify the severity 
and duration, as well as the resulting implications on the treatment of the incident. The 
degree of damage to the patient as a result of an AE is described in Table 2. 
However, it should be noted that, apart from the cost in human lives, the failures in 
health care may have other negative consequences, namely (3,9): 
Incident 
Adverse Event 
Adverse Drug Event 
Adverse Drug Reaction 
Yes 
Damage 
occurred? 
During the taking 
of a durg? 
There is a 
causal link? 
Yes 
Yes 
Figure 6 - Representation of the relationship of the terms: incident, AE, ADE and ADR. 
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!!  Loss of confidence in the health units and their professionals by the users, with 
consequent deterioration of relations between them; 
!!  Frustration on the part of health professionals for not being able to provide the 
best possible care; 
!!  Reduced ability to achieve the results planned by health facilities, with direct 
consequences on the quality of care. 
!!  Increased social and economic costs - increase in days of hospitalization, reduced 
productivity, suffering and emotional distress for the patient and family. 
 
  Table 2 - Degree of damage to the patient (6) 
 
Identify where and when did the mishaps occur during the provision of health care and 
change processes in order to reduce the possibility of damage, requires reliable data on the 
occurrence of preventable AE. According to WHO, the insecurity in health care is a serious 
public health problem, constituting a major cause of morbidity and mortality worldwide (10). 
Through a meta-analysis involving 39 prospective studies conducted in the United States 
of America (USA) over a period of 32 years, it was estimated that in 1994 died approximately 
106 000 patients hospitalized due to severe ADR constituting the 4th-6th leading cause of 
death that year (11,12). In the early twenty-first century, the report "To err is human" 
published by the Institute of Medicine (IOM) has strengthened the concern previously 
raised. According to results released it was estimated that each year die about 44-98 
thousand patients in the USA due to damage resulting from healthcare and not of their 
None The consequence in patient is asymptomatic and do not require treatment. 
Mild 
The consequence in patient is symptomatic, with mild symptoms, loss of 
functions or intermediate or minimum damage of short duration, without 
intervention or with minimum intervention required. 
Moderate 
The consequence in patient is symptomatic, requiring intervention, an 
increase in the stay, or cause permanent/long term damage, or loss of 
function. 
Serious 
The consequence in patient is symptomatic, requiring intervention to save 
the life, major medical/surgical intervention, shortens life expectancy or 
cause permanent damage large/long term, or loss of function. 
Death In the balance of probabilities, the death was caused or anticipated in the short term by the incident. 
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illness, assuming a high mortality rate compared to the values attributed to diseases such 
as Acquired Immunodeficiency Syndrome (AIDS) and breast cancer (9). Around the same 
time, also in Europe were beginning to release data on the impact of AE. According to the 
report "An Organization with a Memory," in the United Kingdom (UK), in 1999, at least 400 
patients died or were seriously injured by AE with medical devices and nearly 10 000 people 
suffered serious ADR. The global estimate is that every year there are about 850 000 AE in 
the british national health service, which translates into 2 billion pounds in additional hospital 
day costs (13,14). Alongside these publications, also a spanish study showed that 9.3% of 
patients in Spain in 2005 suffered AE, of which 42.8% were considered preventable (14). 
Based on the results of national surveys and interviews, the Commission of the European 
Communities (CEC) estimates that between 8 and 12% of inpatients in European Union 
(EU) hospitals are AE victims during their treatment (14). 
In the case of Portugal, the impact of failures on patient safety is not fully known because 
there is not much information available about the topic. However, the recent study 
"Segurança do Doente" held by the national school of public health takes the first steps in 
research in this area. This study was conducted in three public hospitals in the Lisbon region 
and was based on the analysis of the information contained in the medical records of a 
sample of 1669 patients admitted in 2009. According to the results of the study, was 
recorded a rate of AE incidence of 11.1% (at the 95% confidence interval), where about 
53.2% of the cases were considered preventable. As regards to the clinical impact, the 
presence of damage or permanent dysfunction occurred in 5.7% of cases and 10% mortality 
occurred. In 58.7% of cases there was prolongation of hospital stay, with an average of 10.7 
days (with the respective additional costs) (5). With regard to distribution by age groups, the 
number of AE varied in proportion of older age (5). In general, the results reported in this 
study demonstrate that the national picture is not very different from those described in 
identical studies conducted in other european countries or the United States of America 
(USA). 
Although incidents are harmful in any clinical context, oncology poses particular 
challenges, as it is full of uncertainties and can be difficult to see if it really was a medical 
error (15). This becomes even more complicated due to the toxic nature of many of the 
therapies used in treating cancer and, on the other hand, due to the fact that there is a 
higher incidence of this disease in the elderly population (15). It is known that elderly 
patients are more likely to experience AE. This fact can be explained by the higher number 
of chronic diseases present and taking multiple concomitant medications in a prolonged 
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form, resulting in a change in the processes of excretion and elimination and the levels of 
plasma proteins (15). Therefore, despite all precautions, the exposure of the population to 
cancer chemotherapy is associated with a considerable risk of severe AE for patients, and 
there is a serious potential for medical errors (16). In 2009 it was published a study by the 
university of Freiburg medical centre (Germany) which evaluated the quality and safety of 
cancer treatment, with regard to medical errors associated with chemotherapy and severe 
AE resulting from this. According to the results released, during the two years of the study 
there were detected medical and administrative errors in 17.1% of cases of chemotherapy: 
3.8% of the errors involved problems in the order of treatment (dose, drug), 4.5% were 
related to faults in the patient information (height, weight, cycle), while in 8.7% of the errors 
was missing informed consent signed by the patient (16). Concerning the AE, it is known 
that anticancer therapies carry a large number of associated complications, such as 
myelosuppression (leucopenia, neutropenia, thrombocytopenia), infections, nausea, 
vomiting and diarrhea (17). As these complications are usually related to the properties of 
the drugs involved, the study mentioned did not focused on them, and tried to identify 
avoidable serious AE in clinical practice, to attend on them and ensure a safer delivery of 
care (Table 3) (16). As can be seen by the data in table 3, despite the efforts of health 
professionals, still occur severe AE that can be effectively avoided or minimized assuming 
an error monitoring position. Proof that this is possible is that at the end of the study 
presented, the error rate intercepted by the working group was around 99.9%, with only 
three serious ADR associated with chemotherapy occurred due to incorrect treatment or 
orders not intercepted (16).  
 
 
 
Severe AE Number of cases Percentage 
Unexpected death 71 40,8% 
Transfer to the intensive care unit 66 37,9% 
Unexpected operations 5 3,8% 
Extravasation of anticancer drugs 12 6,9% 
Others 20 11,5% 
Total 174 100% 
Table 3 - Classification of severe AE occurred in cancer patients treated with chemotherapy 
(adapted from (16))  
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The decrease that occurred in the error rate was achieved through the implementation 
of efficient surveillance systems, important safety verification tools to ensure that cancer 
treatments are delivered to patients with fewer errors. 
Similar to what happens in chemotherapy, when about two-thirds of cancer patients 
undergo radiation therapy, adverse reactions may arise (18). Generally, AE begin in the 
second or third week of treatment and may persist for several weeks after the last session. 
The EA associated with radiotherapy can be classified as acute – occur during treatment or 
shortly after its completion and generally disappear within four to six weeks – or late – 
observed months to years after completion of treatment and often permanent (18,19). As 
radiotherapy is a localized treatment, the radiation affects only the area of the irradiated 
body. However, it is common for patients to manifest asthenia, being particularly enhanced 
if they are receiving other treatments simultaneously (18,19). Most side effects disappear 
after treatment, although some persist, recur or develop it later. In addition to general side 
effects, some AE of therapy depend on the type and location of the radiation, as can be 
seen in table 4. 
 
Table 4 – Acute AE of radiation therapy, by tumor location (adapted from (19)) 
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Myocarditis 
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Abdominal pain 
Rectal 
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Gynecology 
Colo-Retal 
Others 
Skin and  
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           Erythema Dermatitis 
 
Taking into account the numerous AE that may arise, it becomes clear that the 
monitoring of the safety of the treatments is an essential element in the effective use of 
high-quality medical care. The implementation of effective surveillance systems is critical to 
 
 
 
  
16 
make proper management of toxicity associated with the treatments and to provide a safer 
and more benefits treatment with less damage to the patient. 
Given this panorama, it is essential to identify factors that may contribute to insecurity 
in health care. A very mentioned problem relates to the decentralized and fragmented 
nature of care (9). When patients are seen by multiple providers in different contexts, it is 
not always assured full access to information, making it easier the occurrence of errors or 
not allowing early detection of AE (9). On the other hand, the absence of general and 
specific guidelines setting out actions focused on analyzing the causes of the errors, allied 
to insufficient information, inadequate and difficult to obtain, constitute additional difficulties. 
Finally, the prevalence of a blame culture towards the failures and consequences, 
associated with the underutilization of the AE reporting system, stops improvements in this 
area (3). 
Faced with this evidence, both the WHO and the EU have recommended to several 
countries to assess and monitor the patient safety culture in healthcare units, in order to 
introduce changes and achieve better safety and quality levels (20). Incidents can be 
prevented through designing a safer health system, in order to make it easier to perform the 
action correctly and difficult to do anything wrong. Health organizations should aim to 
develop a "safety culture" so that all processes are focused on increasing the safety of 
patient care. One of the most important attributes of organizations with high reliability is a 
concern on the possibility of failure, admitting that mistakes exist and train professionals to 
recognize these failures (20). 
In Portugal, the recommendations of international organizations were heard and patient 
safety is now a priority of the national strategy for quality in health 2015-2020, which is part 
of the national plan for patient safety (20). The first phase of development of safety culture 
involves the assessment of the current safety culture of healthcare organizations. By 
standard no. 025/2013 of 24 December was instituted this assessment, settling stages of 
the process of assessing and monitoring the patient safety culture in the national health 
system. In August 2015 the report of this study, promoted by DGS and the Portuguese 
Association for Hospital Development (Associação Portuguesa para o Desenvolvimento 
Hospitalar – APDH in Portuguese), was published with data from 55 hospitals in the year 
2014. In this first national assessment, it can be concluded that the patient safety culture is 
not yet widely accepted as a priority by professionals and institutions. About 63% of the 
respondents described not having made any incident report in the last 12 months, a 
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significant proportion feels that mistakes are used against them and the notifier is the focus 
of attention and not the problem itself (20). 
Knowledge and understanding of the incident, as the frequency, causes and impact, are 
a key part of the process of assessment and continuous improvement of patient safety and 
healthcare quality (21). Pharmacovigilance plays an essential role in the early detection of 
risks of medicines. Each drug is tested on a relatively small proportion of the population 
before it is approved for use by the general population, where the ADR that have not been 
previously detected can arise. Thus, pharmacovigilance plays a key role in benefit/risk 
assessment and the criteria and methods for therapeutic use (21,22). At the national level, 
since 1992 there is the National Pharmacovigilance System (Sistema Nacional de 
Farmacovigilância – SNF in Portuguese) that is capable of monitoring the safety of 
medicines. The role of the SNF is to detect, collect, evaluate and understand information 
about ADR and to establish the responsibilities of the marketing authorizations holders of 
medicinal products, health professionals and health authorities (11,22). The establishment 
of such systems is particularly relevant in terms of public health protection of citizens and 
requires appropriate involvement of all stakeholders (11). The surveillance of medicinal 
products focuses mainly on spontaneous reporting of ADR and suspected severe ADR 
performed by health professionals and users to the regional unit of pharmacovigilance or to 
Infarmed, by completing an online form, paper or by phone (22). Although one of the major 
problems identified for the SNF is high underreporting rate, 2012 data show that the 
spontaneous reporting ADR has evolved positively, quite close to the value of 200 
reports/million inhabitants recommended by WHO, placing the country in a favorable 
position regarding this issue (22). In the national context, all reports of suspected ADR are 
evaluated, it is allocated to each a degree of probability and a causality assessment is 
accomplished through the global introspection method or clinical diagnosis (22). With regard 
to its participation as a member of the Risk Management Committee on Pharmacovigilance 
Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), Infarmed 
put Portugal in 2015, in the 3rd position in european system of evaluation as 
pharmacovigilance rapporteur (responsible for monitoring and evaluation of medicinal 
products in Europe) (23). With regard to Medical Devices (MD) it is up to National Authority 
of Medicines and Health Products, I.P. (Autoridade Nacional do Medicamento e Produtos 
de Saúde – INFARMED in Portuguese) to ensure the supervision of them and maintenance 
of the National Surveillance System of MD. This system aims to minimize the risks of the 
use of MD and ensure the implementation of preventive and corrective measures, 
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encouraging the reporting of incidents with MD (24). There must be notified through 
appropriate forms available, all suspected of a serious event related to the MD – life 
threatening situations that put life at risk, cause disability or permanent injury, hospitalization 
or prolongation of that, which causes suffering, anomaly or fetal death (24). 
Alongside these two systems, at the end of 2012 the DGS also made available to health 
professionals and citizens, the National System of Incidents – NOTIFICA. This system is 
structured in accordance with the recommendations of WHO (adopting the 13 kinds of 
incidents defined in the ICPS) and intends that the errors to be reported confidentially, either 
by health professionals or by citizens, so that they can be examined individually and that 
teams can learn from the error (25,26). It is characterized for being an online, anonymous 
and non-punitive platform, which allows the management of incidents and AE, occurring at 
all levels and areas of healthcare units of the health system. According to the 3rd quarter of 
2015 monitoring progress report, the most reported incidents, either by professionals or 
citizens, are relate to clinical procedures, administrative and infections (27). 
The occurrence of preventable Serious Adverse Event (SAE) in health care suggests, 
although it does not prove, that there is a failure in the health organization efforts to 
safeguard patient safety. Therefore, AE reporting systems are seen as an invaluable 
warning systems, and are strongly recommended in all institutions who undergo external 
accreditation processes, either through the Joint Commission on Accreditation of 
Healthcare Organisations (JCAHO) or Caspe Healthcare Knowledge Systems (CHKS) 
(11,28,29). With regard to pharmacovigilance, the role of the notification system is 
irreplaceable, with proven efficacy and a good track record with respect to preventing 
potential problems and identifying new or unknown AE (11,12).  
Given this background, it is easy to see that the AE are clearly important for health 
organizations, not only because of its impact on patients, but also because they can provide 
insight into the quality of health care and promote improvement in performance (9). It is 
consequently crucial that patient safety, reporting and resolution of AE, rather than a 
necessity, should fall in routine care. It is imminent to implement changes to promote a risk 
management culture and make all activities safely to patients, reducing the risk of AE (9). 
 
 
 
 
 
  
19 
2.1! Regulatory Framework 
In order to reduce the number of AE, by collecting better safety data on clinical medicine 
and procedures, there have been many efforts to make legislation in this area most 
complete as possible. In 2005, the European Commission initiated a review of the european 
system of security monitoring, which resulted in the adoption of the new directive and the 
regulation in December 2010, causing the biggest change in the regulation of human 
medicines in the EU since 1995 (30). Therefore, in this report were consulted some 
documents of the current european and national legislation pharmacovigilance, which apply 
to providers of healthcare units and its professionals: 
!! Directive 2010/84/EU of 15 December – amending Directive 2001/83/EC in 
order to strengthen EU law in pharmacovigilance; 
!! Decree-Law nr. 128/2013 of 5 of September, which is the 8th alteration to the 
Decree Law nr. 176/2006. 
In addition to legislation, there is a guideline with procedures designed to facilitate the 
performance of pharmacovigilance in the EU – the Good Pharmacovigilance Practice 
(GVP). Of its various modules, those that have had the most interest for this project were 
the module V – risk management systems and module VI – management and reporting of 
adverse reactions to medicinal products. For the analysis of AE and incidents, it was also 
used the orientation nr. 011/2012 of the DGS. 
With regard to risk management, despite not having legal requirements, there has been 
consulted some documents, which are used as a reference for the implementation of risk 
management systems in institutions, such as the ISO 31000 and the International 
Conference on Harmonisation (ICH) Guideline Quality Risk Management - Q9.  
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2.2! Risk Management 
All activities of an organization involve risk, which is commonly defined as the 
combination of the probability of occurrence of harm and the severity of that damage (31). 
When it comes to health care, risk management includes all clinical and administrative 
activities undertaken to identify, assess and reduce the risk of injury to patients, staff and 
visitors and the risk of loss to the organization itself (32). The risk is inherent in everything 
the organization does, from treating patients to determine the priorities of care. Therefore, 
risk management depends on knowledge of how all the components of the system interact 
with each other. Organizations manage risk by identifying it, analyzing it and then evaluating 
whether the risk is acceptable or should be reduced. Thus, along with a structured training 
program for all health unit staff, it can set four main pillars that are the foundation for the 
operation of a risk management program (33): 
1. Incident Reporting System (IRS); 
2. Identification and assessment of risk; 
3. Monitoring of the patient safety indicators; 
4. Audit as continuous improvement instrument. 
 
2.2.1! IRS 
The main purpose of an IRS is generating signals that lead to the early identification of 
potential problems (33). In this way, I intend to analyze the contributing factors, with a view 
to establishing a plan for improvement in order to prevent their recurrence (11,29,33). The 
success or failure of any IRS depends on the active participation of reporters. In most cases, 
the shame and the fear of punishment by professionals, lack of utility perception (especially 
if there is no adequate feedback) and the difficulty in understanding what constitutes an 
incident, contribute to the great limitation of these systems: underreporting 
(11,22,29,33,34). Thus, it is essential to increase the knowledge of the healthcare team 
about patient safety through training, to instruct the understanding of the different types of 
incidents, their causes and consequences(22). 
In each reported incident, is critical to determine whether it reached or not the patient, if 
required a new therapeutic intervention, if prolonged hospital stay and caused some 
damage (29). If done in a systematic manner, this research allows us to determine the 
priority areas of intervention, either by greater frequency or the more serious the damage 
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caused (29). Effective implementation of an IRS in a healthcare facility is a slow process 
that to function properly, needs to (3): 
!! Develop a culture of responsibility and not punishment; 
!! Analyze incidents with focus on the system rather than the individual; 
!! Facilitate communication of AE and allow feedback to stimulate the improvement, 
preventing new risk events; 
!! Simplifying the act of notification: few items, but fundamental. 
In short, table 5 lists the characteristics that have been identified by several authors as 
pillars for a successful notification system. 
 
Table 5 - Characteristics of a successful incident reporting system (adapted from (35)) 
Not punitive Notifiers are free of fear of retaliation or punishment of others, as a result of the notification. 
Confidential Patient and notifier identities are never revealed to a third party. 
Independent The program is independent of any institution with the power to punish the notifier or organization. 
Analyzed by 
experts 
The reports are evaluated by experts who understand the clinical 
circumstances and are trained to recognize the underlying causes. 
Timely The reports are reviewed promptly and the recommendations are quickly disseminated to the appropriate involved. 
 
Oriented 
systems 
 
The recommendations focus on changes in the systems, processes or 
products, rather than on individual performance. 
Responsive 
The group that analyzes the incidents are able to disseminate the 
recommendations and answer any questions that may arise during the 
implementation of the measures proposed process. 
 
Since this is a reactive approach, which is made after the occurrence of a failure, for 
the analysis of an incident it is necessary to have in mind that an incident is associated with 
a chain of underlying events, with several factors which have contributed to their 
occurrence. Therefore, the analysis should be based on the identification of these factors 
and one of the measures that can be used is the Root Cause Analisys (RCA), shown in 
figure 7. According with the ICPS, RCA is an iterative systematic process whereby the 
factors that contribute to an incident are identified, to reconstruct the sequence of events, 
repeating the question "why" until the underlying root causes are clarified (6). 
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Figure 7 – Steps of RCA (adapted from (33)) 
 
The steps followed in the RCA are (36): 
!! Description of the event: Using medical records, the AE and activities leading up 
to it must be described in detail. Must be done the record of the incident, 
specifying the injury or potential injury to the patient. It is important to 
chronologically describe the incidente through questions such as “when did it 
occur?” or “what service areas were affected?”; 
!! Identification of the Proximate Cause(s) (PC) that led to the event: The PC 
explains why the event occurred. For example, an ADR (the event) occurred 
because the physician made a request for the wrong antibiotic (PC) that the 
pharmacy dispensed (PC) and a nurse administered (PC). These PC of AE are 
flaws in the healthcare process, consequently leading to errors. It may be useful 
to build an event diagram, showing the steps in the process that failed. 
!! Identification of the Contributing Factors (CF) that led to the PC: CF permit errors 
to occur. For example, a nurse who forgot to administer a dose of medication 
may have been required to do a double shift. Thus, fatigue and staff shortages 
were the CF to this medication error. CF to AE often fit into the following 
categories: human resource issues, information availability, environmental 
issues, culture and communication among clinicians. 
Record the incident and 
collect all related 
information
Chronologically describe 
the incident
Identify problems 
(brainstorming)
Explore the problem by 
identifying the causes
Identify measures to 
improve the quality and 
safety of care
Implement, disseminate 
and monitor improvement 
measures.
1 
2  
3 4 
5 
6 
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!! Identify measures to improve the quality and safety of care and implement, 
disseminate and monitor these measures. 
Regarding the AE with drugs, whenever there is a suspicion of an ADR, or an incident 
with a MD, it is the obligation of the health institution to notify the INFARMED or regional 
pharmacovigilance units, by appropriate forms available. 
 
2.2.2! Identification and assessment of risk 
The methods of identification and risk assessment are a proactive approach that is 
intended to realize if our activity potentiates adverse and unexpected events, in order to 
create preventive mechanisms and avoid that these AE occur (figure 8) (33). The 
organization should define the criteria to be used to assess the significance of the risk, 
reflecting the values, objectives and organization of resources. It is appropriate that the 
factors to be considered include aspects such as (37): 
!! Nature and types of causes and consequences that can occur and how they will 
be measured; 
!! How probability is going to be defined; 
!! Evolution in the probability of the time and/or consequences; 
!! Risk level to be determined; 
!! The level at which the risk is acceptable. 
 
1.! Risk assessment consists on the identification of hazards and the analysis and 
evaluation of risks associated with exposure to those hazard. Quality risk assessments 
begin with a well-defined problem description or risk question (31,37). 
!!  Risk identification is an organized use of information to identify hazards 
referring to the risk question or problem description. The organization should 
identify sources of risk, causes and potential consequences. Information can 
include historical data, theoretical analysis, informed opinions, and the concerns 
of stakeholders. The identification of risks addresses the question "What might 
go wrong?" (31,37). 
!! Risk analysis involves understanding the risks, namely the estimate of the risk 
associated with the identified hazards. It is the process of linking the probability 
of occurrence and severity of damage. The risk analysis may be performed with 
various levels of detail depending on the risk involved, the purpose of the 
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analysis and information available. Depending on the circumstances, the 
analysis can be qualitative, semi-quantitative or quantitative, or a combination 
thereof (31,33,37). With qualitative methods it is possible to make a subjective 
assessment of the activities/processes. It is not intended to quantify the 
consequence and probability, these assume a purely qualitative dimension 
(33,36). The semi-quantitative evaluation method associates a numerical value 
to the probability and consequences identified. In the quantitative method there 
are used sophisticated techniques and mathematical models that take into 
account the standards of regularity and frequency of the event, to calculate the 
probability values. For its complexity this method is used at very high risk areas, 
such as chemical or nuclear industries (33,36).  
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Despite the inherent subjectivity, the qualitative method has the advantage of 
being simple, requiring advanced mathematical knowledge. The table 6 shows 
the levels of risk classification resulting from the semi-quantitative assessment 
of the consequence and probability of risk detected, recommended by the 
National Patient Safety Agency (NPSA) (33,36,38). 
!! Risk evaluation compares the risks identified and analyzed according to 
established risk criteria. The purpose of evaluation is to help in making decisions 
based on the results of the risk analysis on which risks need treatment and the 
priority to the implementation of treatment. When making an assessment of the 
effective risk, the robustness of the data set is important because it determines 
the output quality. The output of a risk assessment is either a quantitative or 
qualitative estimate of risks (31,37). 
 
 
 
 
 
 
 
2.! Risk control involves decisions to reduce to an acceptable level and/or to accept risks. 
The treatment of risk involves selecting options to modify the risks and the 
implementation of these options. The amount of effort used for risk control should be 
proportional to the implication of the risk. Decision makers might use different 
procedures, including benefit-cost analysis, for understanding the ideal level of risk 
control (31,37). 
 
Consequences 
Likelihood 
1 2 3 4 5 
Rare Unlikely Possible Likely Almost certain 
5 Catastrophic 5 10 15 20 25 
4 Major 4 8 12 16 20 
3 Moderate 3 6 9 12 15 
2 Minor 2 4 6 8 10 
1 Negligible 1 2 3 4 5 
1 - 3 Low risk 
4 - 6 Moderate risk 
8 - 12 High risk 
15-25 Extreme risk 
Table 6 - Risk matrix recommended by NPSA (adapted from (38)) 
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!! Risk reduction includes the actions taken to lessen the probability of 
occurrence of harm and severity of that harm (31).  This focuses on processes 
for mitigation or prevention of risk (through improving the detection of dangers) 
when it exceeds a specified acceptable level. Treatment of risks, itself, can 
introduce risks. Thus, monitoring needs to be part of the risk reduction plan to 
ensure that the measures remain effective (31,37). 
!! Risk acceptance can be a formal decision to accept the residual risk or it can 
be a passive decision in which residual risks are not identified (31). For some 
types of problems, even the best risk management practices might not entirely 
eliminate the risk and a strategy to accept and manage the risk might be applied 
(31,37). 
 
3.! Risk communication is the sharing of information about risk and risk management 
between the decision makers and others (31). All interested parties can communicate at 
any stage of the risk management process. It is appropriate that the plans for 
communication and consultation are developed at an early stage and address issues 
related to the risk itself, such its nature, probability, severity, control, treatment or other 
aspects related (31,37). 
 
4.! Risk review should be an ongoing part of the quality management process, and involve 
periodic checks or regular surveillance (31). A mechanism to review or monitor events 
should be implemented to ensure that controls are effective and efficient, information to 
improve the risk assessment process, analyze the events and identify emerging risks 
(31,37). 
 
The process of identification and analysis of risk, regardless of the method used, will 
allow to distinguish between the identified risks, the most serious which therefore require a 
priority intervention. Risk analysis with techniques such as Failure Mode Effects Analysis 
(FMEA), Preliminary Hazard Analysis (PHA) or Hazard Operability Analysis (HazOP) allow 
close scrutiny of the processes but require higher availability and training of the team 
(31,33). The objective of FMEA is to identify the critical points of processes, evaluate the 
failures that may occur and their weighting in terms of frequency, severity and risk (31). 
Once failure modes are established, risk reduction can be used to eliminate, reduce or 
control the potential failures. This approach is intended to act in the prevention, with a 
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proactive attitude, complemented by an ongoing notification by the IRS (31,39). It is a 
powerful tool for summarizing the important modes of failure, factors causing these failures 
and the likely effects of these failures. For its part, PHA is an analysis tool based on the 
application of experience or knowledge of a hazard to identify future risks, situations and 
hazardous events that can cause damage, as well as to estimate the probability of a 
particular activity. The tool consists of: 1) identifying the possibilities that the risk event 
happens, 2) qualitative evaluation of the extent of possible injury or damage to health that 
may result, and 3) a relative hazard classification using a combination of severity and 
likelihood of occurrence, and 4) the identification of possible corrective measures (31). 
HazOP is based on a theory that assumes that risk events are caused by deviations from 
the effective intention. It is a brainstorming technique for identifying hazards using so-called 
"guide-words”. Words such as "no”, “more”, “beyond” or “part of" are applied to the relevant 
parameters (e.g., contamination, temperature) to help identify potential deviations from 
normal (31). 
 
2.2.3! Monitoring of the patient safety indicators 
Indicators are a basic tool for health unit management which are used to help to describe 
the current situation of a particular problem, make comparisons, verify changes or 
tendencies (39). They permit to evaluate the implementation of the planned actions over a 
period of time, in terms of quality and quantity of executed health actions (39). An indicator 
can be a rate or ratio, an absolute number or a fact which can be used as a guide to monitor 
and evaluate the quality of care provided to the patient (40).  
 
2.2.4! Audit as continuous improvement instrument 
Audit should be seen as an activity for improving both the quality and safety of health 
care (41). The aspects of performance that are being audited may vary, depending on the 
interests of those in charge of the audit, and the available information. An audit may, for 
instance, deal with prescriptions for specific health problems, test ordering, or compliance 
with disease-specific clinical guidelines. On the other hand, an audit can be based on 
routinely available data from electronic patient records or medical registries, or on data that 
are collected by the health professionals specifically for that purpose (41). To establish the 
frequency and scope of audits, there should be taken into account the existing legal 
requirements, the robustness of a company’s quality risk management activities and the 
results of previous audits/inspections (31).  
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3.!Activities developed during internship 
This chapter intends to describe all the activities, tasks developed and learning 
outcomes acquired during my curricular internship of nine months at Lenitudes MC&R.  
The main functions performed during the internship were activities related to risk 
management, including the development of the risk management manual, the elaboration 
of procedures for AE collection and preparation of periodic monitoring reports. Additionally, 
I had the opportunity to be in contact with different areas, allowing me to performed 
multidisciplinary activities. Some of this activities encompassed tasks related to R&D, such 
collaboration as medical writer, project management and collaboration on resarch meetings. 
The schedule and duration of the activities are identified in the Gantt chart presented in 
figure 9. In the following sections are presented the activities that were developed, related 
to risk management activities and to multidisciplinary activities.  
 
 
 
 
  
 
 
 
 
Figure 9 - Timechart of activities and training sessions developed during the internship. 
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3.1!Risk Management Activities 
As mentioned earlier, my internship began on 1st September of 2015. By this time, the 
Lenitudes MC&R was in the early phase of its activity, going through the licensing process 
for the various activities: surgery, radiotherapy and nuclear medicine. Despite R&D is being 
part of the objectives to be followed in this health unit, at this early stage, it was not possible 
to develop only tasks inserted in this context. Thus, in the first meeting before the internship 
started, it was proposed that it was developed in another equally important area for health 
unit – Risk management and Pharmacovigilance. 
In order to be prepared to carry out activities related to risk management it was 
necessary to carry out an extensive research and review of the available literature. To read 
and understand the international standards, the guidelines of the authorities and do some 
training courses were essential to develop the tasks mentioned in the following chapters. 
 
The risk management activities included the development of the following documents: 
1.! Risk management manual for health facilities Lenitudes; 
2.! Standard record for the process of RCA; 
3.! Standard record for the process of the identification and assessment of risk; 
4.! Incident reporting forms; 
5.! Monitoring of AE associated with clinical practice; 
6.! AE monitoring periodic reports associated with radiotherapy. 
All documents have been developed in a simple way in order to ensure that they are 
easily understood by all staff involved. 
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3.1.1! Risk management manual for health facilities Lenitudes 
Keeping in mind the importance that risk management has for health facilities providing 
health care of high quality and safety, came the opportunity to take the first steps in this 
area in the development of Lenitudes. So, I proposed and developed an early version of 
"Risk management manual" in order to begin to set the strategy to be adopted by health 
units Lenitudes (see annex I). 
According to the rules previously established by documentation control SOP developed 
by the quality system of the unit, the manual has been drafted and is organized into the 
following chapters: 
1.! Summary; 
2.! Introduction – includes a brief description of the structure and organization chart 
of Lenitudes, and shows the importance of risk management for the unit; 
3.! Purpose – presents the main objectives of creating this policy: 
!! To prevent, manage, analyze, minimize, implement actions related to 
clinical risk and non-clinical; 
!! To maximizing the quality of care by reducing the risk to an acceptable 
level; 
!! To provide the effectiveness and efficiency of risk management; 
!! To promote the systematic analysis of risk management performance 
through indicators and audits; 
!! To minimize the costs of risks (human and financial); 
4.! Mission – describes the mission of the risk management system; 
5.! Organization and Responsibilities – describes the major responsibilities of the 
administrative board, the technical support group risk management and other 
groups; 
6.! Risk Management – overview system and its four pillars, shown in Figure 10: 
!! IRS; 
!! Identification and assessment of risk; 
!! Monitoring of the patient safety indicators; 
!! Audit as continuous improvement instrument; 
7.! Hospital emergency plan; 
8.! Policy for sharing information; 
9.! Record of document revisions. 
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In the section six of the manual are given some suggestions on the methods to be 
adopted taking into account the structure and reality of health facilities of Lenitudes. The 
strategy presented was developed by me and reviewed by Prof. Francisco Pimentel. 
With regard to the reactive approach, it is suggested that the RCA team is composed 
by a coordinator of the team, a senior professional, one or two professionals with specific 
knowledge in the area, possibly one or more specialized consultants and a top manager of 
the organization. As the activities associated with RCA constitute a complex process that 
involves a cost which can be significant, it is recommended that not all incidents are 
subjected to this analysis. The decision to perform or not the RCA depends on the severity 
of the incident, its frequency, the contributing factors and likelihood to happen again. The 
JCAHO only requires its implementation in sentinel events, and therefore, it is 
recommended that Lenitudes follows this recommendation. In this regard it should be 
consulted the ‘decision tree of incidents’ to help determine whether or not to perform an 
RCA. The decision must be made before the work of the RCA team starts. In the manual is 
also established that, in the case of Lenitudes MC&R, the incident notification should be 
Risk culture – All professionals play an active role in the system. 
Feedback – Periodic reports with the analysis of the data collected; appreciation of the 
contribution provided; strengthening confidence in the delivery of health care system. 
IRS
• Non-punitive reporting;
• Evaluation and monitoring of AE;
• Analysis of the RCA of sentinel events.
Identification and assessment 
of risk
• Proactive approach;
• Failure Mode Effects Analysis;
Monitoring of the patient safety 
indicators
• Comparison/verification of changes or 
tendencies;
• Evaluation of the implementation of 
planned actions.
Audit as continuous 
improvement instrument
• Periodic;
• Routine based on available data from 
electronic medical records, or based on 
data that is collected specifically for this 
purpose.
Risk Management
Figure 10 - Representative scheme of the Risk Management System (scheme designed by the author).!
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made by the record of the occurrence in the "Risk Management Platform” (initially, this 
platform is composed of forms in paper format). Thus, whenever there is a suspicion of an 
ADR, an incident with a medical device, or a problem in a procedure, it shall be recorded in 
accordance with the respective internal procedures of the institution. 
Regarding the proactive approach, in the manual it is suggested to adopt a method of 
semi-quantitative risk analysis as recommended by the NPSA, due to its easy use and 
interpretation. It is also presented the algorithm for identification and risk assessment 
designed to guide the implementation of this process. 
With regard to patient safety indicators, taking into account the health unit 
characteristics, the following indicators were defined to be monitored in order to reflect the 
safety of care: 
!! Rate of return to the operating room unplanned; 
!! Infection rate of surgical wound; 
!! Reintervention rate up to 30 days of post-operative; 
!! Mortality rate up to 30 days of post-operative; 
!! Infection rate of operated patients; 
!! AE rate associated with ambulatory surgery; 
!! Rate of haemorrhage/haematoma postoperative annually; 
!! Number of reported AE associated with medication; 
!! AE rate associated with transfusions. 
This document should be reviewed at least once a year. However, considering the 
development phase of Lenitudes, it should be updated whenever new information arise and 
is approved. 
 
3.1.2! Standard record for the process of RCA 
This standard record was written by me under the reactive approach – namely the RCA 
– presented in the risk management manual. If a particular incident that occurred with 
significant gravity during clinical practice in Lenitudes is notified, it is advisable to investigate 
the causes and contributing factors that provided the occurrence of the incident. This 
process requires a lot of retrospective analysis, check in detail what has been done and it 
is essential to document all the steps covered. Thus, and according to orientation number 
011/2012 of the DGS, a standard record was created in order to keep documentation 
organized, tracked, and updated. This summary should contain the main topics of the RCA, 
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such as a brief description of the incident/clinical event, date and time of the incident, notifier 
name and service in he/she which performs functions, the proximate causes, contributing 
factors and recommendations for possible measures to be taken to prevent the recurrence 
of the incident (see annex II). The responsibility of writing this record is of members of the 
RCA team. 
In addition to this record, at the end of the process, should be attached the following 
documents with greater detail on the RCA process: 
!! Flowchart with the sequence of events – at the end should be possible to define 
what happened, with whom, when, where, why, how it happened and, if 
possible, the increased cost associated with the incident; 
!! Flowchart from the sequence of expected or defined procedures in accordance 
with the rules established in the institution; 
!! Improvement actions list, implemented immediately after the incident; 
!! Literature review related to the nature of the incident under investigation; 
!! List and description of existing barriers; 
!! List of CF obtained through brainstorming, which may have been crucial for the 
development of the incident; 
!! List of improvement plans including indicators, temporal goals and objective 
measures; 
!! Results report. 
This document should be reviewed at least once a year, if there is no indication on the 
contrary. 
 
3.1.3! Standard record for the process of the identification and 
assessment of risk 
In order to proceed taking into account the recommendations described in the risk 
management manual, this record was developed under the proactive approach to risk 
management. Contrary to the RCA which is developed after an incident has taken place, 
trying to identify the causes to minimize recurrences, the proactive approach aims to identify 
and assess the risk before the incident occurs. One of the techniques recommended in the 
manual is FMEA approach. This technique attempts to identify, for a specific process, the 
critical points, the failures that can occur and their weight in terms of frequency, severity 
and risk. 
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Once the potential methods of failure are identified, risk reduction measures can be 
applied to eliminate or control the risk. Therefore, if a situation in clinical practice justifies 
initiating this process, it is crucial to document the information gathered in all these steps, 
in an objective way and following the quality standards. In this sense, I drafted the standard 
record in question, including the following fields that summarize the main topics of this 
approach (see annex III): 
!! Date; 
!! Name of the procedure/medical device; 
!! Risk class equipment (if applicable); 
!! Hazards/risks identified; 
!! Risk assigned by a semi-quantitative assessment (consequnce x probability); 
!! Risk control measures. 
The completion of this record is the responsibility of the members of the risk 
management team that perform the procedures for risk analysis and identification. 
This document should be reviewed at least once a year, if there is no indication on the 
contrary. 
 
3.1.4! Incident reporting forms 
3.1.4.1! For MD 
When I started my internship at Lenitudes MC&R had already been produced some 
documents in the context of risk management. One of this documents was a form for 
recording radiological events, prepared by the radiation therapy team. In this document it is 
recorded the place of occurrence, the person who identified the class of occurrence (near 
miss, incident without damage, AE, sentinel event), consequences and preventive 
measures. However, it was missing develop a notification form for incidents in an important 
area: MD. Thus, based on the topics present in the MD incident notification form of 
INFARMED, and existing internal SOP for reporting incidents, I drew up a form for the 
registration of these incidents. This incident reporting form is important to compile 
information relating to incidents in a systematic and uniform manner to all cases. This form 
contains the following fields: 
!! Notifier – name, profession, e-mail, date of notification, signature; 
!! Suspected MD – commercial name, model, serial number or batch, 
manufacturer, distributor; 
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!! Information about the patient – identification (name initials), date of birth, sex; 
!! Incident – date and place where the incident occurred, description, 
consequences for the patient, evolution of the patient (at the time of notification), 
similar events; 
!! Additional comments. 
Any health care professional who, due to the clinical activity, encounter an incident with 
an MD, must notify the case to the risk management team by completing this form. This 
document should be reviewed at least once a year, if there is no indication on the contrary. 
 
3.1.4.2! For drugs 
Apart form for reporting incidents involving MD was also necessary to draw up a form 
focused to the ADR notification. Once the clinical activity was initiated in Lenitudes MC&R, 
it became necessary to create a support for the characterization of ADR which occur during 
the course of treatment or diagnostic tests using drugs (eg. cardiac stress test by chemical 
stress). In this sense, I developed a form adapted to the reality of the clinic which contains 
the following fields (see annex IV): 
!! Patient information (process number, name, date of birth, age, sex, weight and 
height); 
!! Characterisation of ADR (start and end date, description, severity and outcome); 
!! Information about the suspected drug (dose, frequency, route of administration, lot, 
expiry date, start and end date and therapeutic indication); 
!! Information about concomitant medication (dose, frequency, route of administration, 
lot, expiry date, start and end date and therapeutic indication); 
!! Other relevant information (similar history of ADR, allergies, pregnancy, re-exposure 
to the drug); 
!! Management of ADR (drug therapy support, patient hospitalization, classification of 
ADR); 
!! Information about the notifier (name, profession, personnel number, e-mail, 
signature and date). 
This document presents with a similar format to the forms of spontaneous reporting 
provided by INFARMED, integrating the required fields to register the case and forward it 
to the responsible authority. This document should be reviewed at least once a year, if there 
is no indication on the contrary. 
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3.1.5! Monitoring of AE associated with clinical practice 
The development of a positive clinical outcome depends, among other factors, of an 
adequate management of the toxicity of treatments provided. When this fact is not taken 
into account, the AE associated with treatments often cause morbidity for patients. In this 
sense, the monitoring of the safety of treatments, especially anticancer therapies whose 
toxicity is considerably high, it is essential for a high-quality medical care (16). 
It was in this context that in the first phase of my internship, it was proposed to develop 
an AE reporting system in chemotherapy. This reactive approach, where the problem 
analysis is made after notification, aims to evaluate the toxicity of the different therapeutic 
regimens. The Lenitudes MC&R wanted the notification of AE to occur in an integrated 
manner in the clinical record system. To this end, it was necessary to previously input into 
the computer system a database with the main AE associated with each chemotherapy 
regimens used. 
In this sense, I started to define some of the most frequent therapeutic regimens for 
each of the most common cancers, with the help of the medical director and the 
pharmaceutical responsible. After that, I collected information in the medical literature about 
the toxicity associated with these treatments, and defined the percentage theoretically 
expected for the occurrence of each AE. The example below shows the result of this 
exercise performed for three of the most common regimens in breast cancer therapy, 
colorectal and lung cancer – FEC, FOLFOX 6 and Pemetrexed+Cisplatin, respectively 
(tables 7,8 and 9).   
 
Table 7 – Most frequent AE of FEC regimen for the treatment of breast cancer (adapted from (42)) 
 
 
 
 
FEC 
100 
 
N=276 
Leukopenia/ 
Neutropenia 
Grade 3-4 
Toxicity 
Anemia Toxicity Other Grade 3-4 Toxicities Emetogenic potential 
Selected 
Consequences 
of AEs 
Neutropenia  
25% 
Grade 1-2 42% 
Infection (Grade 3) 3% 
Day 1 – level 
5 
4 cases of 
delayed cardiac 
toxicity 
Stomatitis 4% 
Grade 3 1% Alopecia 79% 
Nausea/Vomiting 35% 
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Table 9 - Most frequent AE of Pemetrexed + Cisplatin regimen for the treatment of Non-small Cell Lung 
Cancer (adapted from (43)) 
Pemetrexed  
+ Cisplatin 
 
 
 
N=839 
Leukopenia/ 
Neutropenia Grade 3-4 
Toxicity 
Anemia 
Toxicity Other Grade 3-4 Toxicities 
Emetogenic 
potential 
Neutropenia 15.1% 5.6% 
Febrile Neutropenia 1.3% 
Level 5-4 
 
Alopecia (any grade) 11.9% 
Thrombocytopenia 4,1% 
Nausea 7.2% 
Vomiting 6.1% 
Fatigue 6.7% 
Dehydration (any grade) 3.6% 
Transfusions 16.4% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FOLFOX
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
First line 
N=110 
 
 
Second  
line 
N=82 
Leukopenia/ 
Neutropenia Grade 
3-4 Toxicity 
Anemia Toxicity Other Grade 3-4 Toxicities Emetogenic potential 
Selected 
Consequenc
es of AEs 
First line  First line  First line 
Day 1 – 
level 4 
 
 
Day 2 – 
level 2 
1 therapy-
related 
death with 
FOLFOX 
when used 
as first line 
 
 
 
 
 
11% of 
patients 
discontinued 
therapy due 
to toxicity 
Neutropenia  
Grade 3 31% Grade 1 39% 
Thrombocytopenia 
(Grade 3) 5% 
Mucositis 
(Grade 3) 1% 
Neutropenia 
Grade 4 13% 
Grade 2 12% 
Neurological 
(Grade 3) 34% 
Diarrhea 11% 
Fatigue 
(Grade 3) 3% 
Grade 3 3% 
Nausea 
(Grade 3) 3% 
Vomiting 
(Grade 3) 3% 
Second line  Second line  Second line 
Neutropenia 
Grade 3 15% Grade 1 35% 
Thrombocytopenia 
(Grade 4) 1% 
Neutropenia 
Grade 4 2% 
Grade 2 9% 
Mucositis 
(Grade 3) 4% 
Neurological 
(Grade 3) 20% 
Nausea 
(Grade 3) 6% 
Grade 3 2% 
Diarrhea 5% 
Fatigue 
(Grade 3) 5% 
Grade 4 1% Vomiting (Grade 3) 5% 
Table 8 - Most frequent AE of FOLFOX 6 regimen for the treatment of colorectal cancer (adapted from (42)) 
 
 
 
 
 
  
39 
 
  After being collected the desired information, it was necessary to structure the way AE 
should arise in the computer system to be recorded. It was intended that the notification 
was carried out in a simple and consistent way in all registers. In this sense, in addition to 
standardizing the definition of AE, it was also desirable to involve the possible degrees of 
damage caused. For this purpose, based on the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.3 from National Cancer Institute (NCI), I elaborated and proposed the 
layout shown in table 10 to be inserted into the computer system, where each AE is defined 
and its severity is graded into levels one to five (44). Thus, the health professional begins 
by typing the name of the incident in a field intended for this purpose. After, the name is 
recognized as an existing term in the database, and automatically arises the definition of 
AE and characterization of each of the five degrees of damage. Then, the professional 
simply choose a level of severity of the event. With this format, it becomes easier for the 
professional notify the AE and, moreover, reduces human error because it minimizes the 
use of free text fields and the introduction of bias in the input data (eg. different designations 
and classifications).  
  
  
 Although this work was carried out in november 2015, this information was not 
immediately integrated into the system because the computer module intended for 
chemotherapy had not yet been developed. Thus, this work remained in standby mode to 
be incorporated later during the software building process. 
 After I developed this work oriented to the chemotherapy regimens, Prof. Francisco 
Pimentel suggested to expand it to radiotherapy, in order to put the system into practice, 
since Lenitudes MC&R was already receiving several patients for radiotherapy purpose. In 
this sense, I initiated a detailed research on the AE more frequent in radiation treatment. 
Adverse Event 1 2 3 4 5 
Anemia 
Hgb 
<LLN - 10.0 g/dL; 
<LLN - 6.2 
mmol/L; 
<LLN - 100 g/L 
Hgb <10.0 - 8.0 
g/dL; <6.2 - 4.9 
mmol/L; 
<100 - 80g/L 
Hgb <8.0 g/dL;  
<4.9 mmol/L; 
<80 g/L; 
 transfusion 
indicated 
Life-threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
Definition: A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms 
of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft 
systolic murmurs, lethargy, and fatigability. 
Table 10 - Suggested layout for AE section of the computer system, with the example of anemia. 
(LLN – Lower Limit of Normal; Hgb – Hemoglobin )  
 
 
 
 
 
  
40 
 
 Since this is a localized therapy, it is essential to take into account many factors that 
influence the onset of AE: the irradiated anatomical area, the technique used and the 
radiation dose to which the patient is exposed. In a generic way the possible AE, acute and 
late, were grouped taking into account the location of the irradiated tumor and anatomical 
area (table 11). 
 
Similar to what happened with the chemotherapy regimens, it was necessary to search 
for a specific classification for the damage caused by radiation, in order to standardize the 
notification of the AE. The classification adopted was Acute & Late Radiation Therapy 
Oncology Group/European Organization for Research and Treatment of Cancer 
(RTOG/EORTC) Radiation Toxicity Grading which also includes five levels of damage 
caused (45). Aside from being one of the most used classifications in this area, the module 
MOSAIQ Radiation Oncology used in Lenitudes MC&R already contained a section for the 
Area Anatomic location Acute AE Late AE 
CNS 
Brain Earache 
Headache 
Nausea 
Alopecia 
Brain edema 
Radiodermitis 
Hypoacusis 
Chronic otitis 
Pituitary dysfunction 
Cataracts 
Radionecrosis 
Others 
Head and neck 
Odynophagia 
Dysphagia 
Dysphonia 
Xerostomia 
Dysgeusia 
Weight loss 
Radiodermitis 
Mucositis 
Alopecia 
Subcutaneous fibrosis 
Skin ulcerations 
Necrosis (soft tissues, 
cartilage, jaw) 
Odynophagia/Dysphagia/ 
Persistent dysphonia 
Slow healing 
Fistulation 
Fall dental parts 
Chronic otitis: 
hypoacusis 
Apical 
pulmonary 
fibrosis 
Myelopathy 
Chest 
Breast Odynophagia 
Dysphagia 
Dysphonia 
Dyspnoea 
Cough 
Mastalgia 
Pneumoniae 
Pericarditis 
Myocarditis 
Radiodermitis 
Cytopenia 
Breast retraction 
Lymphedema brachial 
Endocarditis 
Myocardial infarction 
Osteonecrosis costal 
Pulmonary fibrosis 
Dyspnoea 
Chronic cough 
Esophageal 
stricture 
Chronic 
pericarditis 
Myelopathy 
Lung 
Others 
Abdomen 
and Pelvis 
Urology 
Nausea 
Vomiting 
Abdominal 
pain 
Diarrhea 
Pollakiuria 
Dysuria 
Nocturia 
Cytopenia 
Rectal tenesmus 
Proctitis 
Sigmoidite 
Radiodermitis 
Scrotal edema 
Rectal stricture 
Colonic perforation or 
obstruction 
Bladder retraction 
Urinary incontinence 
Chronic cystitis 
Vesico/vaginal fistula 
Rectum/vaginal fistula 
Vaginal retraction 
Lymphedema of 
the extremities 
Changes in 
menstrual cycle 
Sterility 
Impotency 
Liver disease 
and 
nephropathy 
Gynecology 
Colo-retal 
Others 
Skin and extremities Erythema Dermatitis Radiodermitis 
Subcutaneous fibrosis 
Lymphedema in 
extremities 
Anchylosis 
Necrosis of the 
bone and soft 
tissues 
Table 11- Acute and late AE caused by radiation, by anatomical location of the tumor (18,19). 
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AE register through this classification. Since there was already a tool for this purpose, there 
was no need to integrate a new database with the definition/classification of AE. Thus, the 
research conducted served to alert and raise the awareness of professionals about the 
incidents associated with this type of treatment, and served as a theoretical support for the 
preparation of the AE monitoring reports presented in the next section. 
 
3.1.6! AE monitoring periodic reports associated with radiotherapy 
 Once performed a literature review regarding the most common AE associated with 
radiotherapy, I proposed to apply this work to clinical practice and monitor the reporting of 
AE in the internal computer system. The data obtained from monitoring records made by 
health professionals was the basis for the preparation of periodic reports. This was a 
dynamic process which required to overcome several stages, from design to conception, 
extraction of data to their interpretation. Since the initial phase up to the stage of structuring 
and validation of the report format, the help of Dr. Fernando Costa, radiation oncologist 
physician in Lenitudes MC&R, who accompanied me throughout all the process, was 
essential. The various steps are shown schematically in figure 11. 
The first step in this process was to identify the information necessary to collect of the 
computerized system to perform a robust analysis of the data. In addition to the type of AE 
and its severity, other elements were essential, such as patient demographics (age and 
gender), the type of cancer (location and histology), stage of cancer, the radiation therapy 
technique used (TT 3D CRT, VMAT), the intent of treatment, number of sessions and the 
conducting of chemotherapy (prior or concomitant). All these data were available and 
accessible in the medical record software. 
1. Identification 
of data to be 
collected from 
the computer 
system
2. 
Establishing 
the method of 
collection and 
construction 
of the 
database
3. Collection of 
data of the first 
month 
(February 
2016)
4. Data 
analysis
5. Document 
review and 
incorporation 
of 
amendments 
suggested by 
the reviewers
6. Final 
approval and 
disclosure
7. Excel 
database 
automatization
8. Elaboration 
of subsequent 
reports
Figure 11 – Representative scheme of the process of developing periodic reports of AE monitoring. 
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1.! Once the fields of interest identified it was necessary to create a database to store 
them. To this end, I created a Excel registry base with all these parameters. The next 
step was to define how this information would be collected from the MOSAIQ software. 
For this purpose, I prepared the SOP for "Collection of AE’s information on MOSAIQ® 
Oncology Information System software" (see annex V). This SOP describes, step by 
step, the data collection method and the process of filling the fields created in the 
database. 
2.! After defining the method of collection and registration of the information, it was time to 
put into practice the procedure and collect data from the first month of radiotherapy 
activity (February 2016). Over several days the data of each patient followed in 
radiotherapy during that month were introduced, featuring in detail all the required 
fields. 
3.! After the construction of the database it was necessary to analyze and interpret the 
information obtained. In this sense, I elaborated the SOP for "Development of AE 
periodic report", where I described orientations for the construction of the document, 
divided into three sections: 
a.! Drafting of the report – purpose of preparing the document, who is 
responsible for its production, which tools are used; 
b.! Report structure – header, contextualization, statistical data analysis, 
conclusion and tables-summary (monthly and semi-annual); 
c.! Report disclosure policy – periodicity of the report, date and method of 
dissemination to the employees of Lenitudes MC&R. 
Based on this SOP, I performed the data analysis, developed charts and graphs 
showing the distribution of the different AE by cancers, radiation technique and 
treatment intentions. The main objective of this statistical analysis was to compare the 
results obtained in Lenitudes MC&R to the findings in the literature. This analysis was 
also important to realize which areas can benefit from an improvement in the approach 
to treatment, or the techniques that exhibit better results compared to predicted in the 
literature. 
4.! After performing the analysis of the results and drawing conclusions about the month 
of treatment, the written document went through two stages of review: one for the 
radioncologist and other for the clinical director of the unit. These reviews were 
essential to set what terms to use, define the most appropriate structure to present data 
 
 
 
 
 
  
43 
 
or add different conclusions. Once the areas for improvement were identified, I 
introduced the changes to the document with the noted suggestions. 
5.! After the changes suggested by the reviewers, the document “followed” for approval of 
the administrative board of Lenitudes and was disclosed for the whole team involved in 
the radiotherapy unit of Lenitudes MC&R. 
6.! Once the final structure of the report defined and approved, it was necesssary to 
automate the data analysis in order to facilitate the treatment of large amounts of 
information. Over several days, I explored the different formulas in Excel “looking for 
the best” to each scenario. In this way, the calculations inherent to the statistical 
analysis is performed rapidly and automatically, which reduces human error. 
7.! After all this process became systematic, periodic reports of subsequent months were 
developed and disseminated by the team, as established on both procedures.  
 
During the internship period I prepared reports of radiotherapy treatments that were 
carried out during the months of February, March, April and May 2016 (see annex VI). The 
main objective of this activity was to gather the available information about the AE 
associated with radiotherapy treatments performed, in an attempt to identify possible areas 
which need improvement or require greater vigilance. Over the months, it was concluded 
that AE are suited as expected in the literature with regard to the causality of the events. 
The most reported AE was the radiodermatitis. The analysis was made based in the 
incidence of AE by type of cancer, age of patients, for performance or nonperformance of 
chemotherapy in combination, or by type of radiotherapy technique used. The balance was 
positive, especially in patients undergoing VMAT technique that is less invasive. When 
compared to technical TT 3D CRT, the VMAT led to the appearance of a smaller number 
of AE in patients treated. The fact that the numbers are positive due in large part to the care 
provided to the patient, the teachings transmitted in the nursing consultation, and the 
adequacy of radiation therapy techniques used in each case. 
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3.2! Multidisciplinary Activities 
As mentioned earlier, although the R&D unit was taking the first steps at the beginning 
of my internship, I had the opportunity to collaborate on some tasks in this area. These 
activities were developed during the entire time of internship and I will describe them in 
more detail in the following sections. 
 
3.2.1! R&D 
 
3.2.1.1! Project Management & Medical Writing 
In addition to the activities that were performed within the risk management system, I 
collaborated in some other projects as medical writer and project manager. 
One of my first assignments was to collaborate in the elaboration of a program for 
workshops promoted by Lenitudes MC&R and Eruditus. The goal was to organize a serie 
of workshops related to the theme of immuno-oncolgy, directed to medical oncologists and 
pulmonologists. Initially there were designed two workshops related to lung tumors and 
liquid tumors (lymphomas and leukemias). I gave my contribution conducting bibliographic 
research on similar programs that had already been made, trying to identify the key issues 
as well as renowned speakers in the area. Subsequently, with the information collected in 
a teamwork, we defined the agenda of the first workshop. A considerable amount of time 
for compilation of information and organization of agenda reflected the care that was taken 
into account for its preparation. 
I also collaborated in another project named ‘Neways: Cancer Network for Aging 
Welfare’. This project intends to discuss two of the great problems of our society: the 
progressive aging of the population and the high incidence of cancer after 65 years. 
Concerning this scenario, there is an imperative need to integrate geriatric skills in the 
treatment of cancer in elderly and adapting the therapeutic strategy to the nature of senior 
individuals. Therefore, this project aims to discuss this subject at national level, and to 
develop activities to improve or optimize the portuguese reality. I had the opportunity to 
participate since the beginning of this project, witnessing all meetings and elaborating the 
minutes of some of these meetings. I collaborated in the organization of the first meeting of 
the steering committee, which marked the official start of the project. At the first meeting, 
there was established the mission and objectives of the project, its image and name. After 
that, I gave a major contribution in writing an editorial in the "Acta Médica Portuguesa", 
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which was developed in order to disseminate the principles of the project within the medical 
community: 
!! Pimentel FL, Oliveira C, Soares J, Veríssimo M. Neways: Cancer Network for 
Welfare Aging. Acta Med Port. 2016;29(4):235–6. 
Simultaneously, I was also involved in project management and medical writing 
activities in the context of a clinical study with the intervention of MD. This clinical study 
arised from investigator initiative, a cardiologist of Lenitudes MC&R, and I collaborated with 
R&D team in project management, namely in distribution of functions and scheduling of 
tasks. In regard to my connection to the area of risk management and pharmacovigilance, 
I was responsible for writing the chapter "Safety Monitoring" of the protocol of this study. I 
also elaborated the forms for reporting SAE and pregnancy, necessary for this and other 
future clinical studies. The first need in the beginning of this task was to understand how to 
build these protocols sections. For this, I searched in the biomedical literature for examples 
of clinical trial protocols to serve as an example of what I wanted to do. This allowed me to 
gain knowledge about the various steps in the elaboration process of these important 
documents. In addition, I also had the opportunity to apply some knowledge in statistics, 
helping to calculate the sample size required for this clinical study. The sample size 
calculation was made with the help of the software G*Power 3.1®. 
Although R&D has not been the core activity of my internship, due to the phase of 
development and growth of the unit, these activities were very enriching, allowing me to 
have different perspectives of the work that can be done in this area. 
 
3.2.1.2! Analysis of investigation fund opportunities for Lenitudes MC&R 
During the time I was in Lenitudes MC&R, I was several times requested to search for 
research opportunities which fitted in the profile and mission of the unit. One of the projects 
for which I searched research opportunities was the Worldwide Cancer Research Fund, 
which intends to fund scientific research that may, in the future, help reduce the incidence 
of cancer or improve cancer survival. For this, I read the information available on the website 
of the initiative and its own regulations. I tried to identify the requirements of the projects, 
the applications dates and see if any of the ongoing projects in Lenitudes MC&R was 
appropriate for the application in the initiative.  
Also in the sense of looking for research scenarios, I had the opportunity to participate 
in the Info Day Research and Innovation Staff Exchanges (RISE), held on 25th of january 
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2016, in the Academy of Sciences, Lisbon. This initiative intended to present the RISE Marie 
Sklodowska-Curie Actions (MSCA) program inserted in Horizon 2020, and to clarify 
potential doubts about it. The MSCA RISE constitute support for mobility and secondment 
of employees in the area of research and innovation. It enables the creation of partnerships 
between academic and non-academic institutions, in countries of Europe and other 
countries. Although it has not made any immediate opportunity for Lenitudes under this 
initiative, the fact of knowing the main advantages and program incentives, the criteria for 
evaluation of the application, the funding conditions and the application dates, allowed to 
be aware of the future projects of Lenitudes that can be appropriate for this initiative. 
I also had the opportunity to participate in a clarification session on the legal and 
financial aspects of the opportunities Horizon 2020, for 2016/2017 calls. This session, 
occurred on 6th of may 2016, was very enlightening since were presented a number of 
specific funding opportunities for the area of health, allowing the start of the designing of 
application hypotheses for Lenitudes MC&R. 
 
3.2.1.3! Clinical research coordination 
As a result of above-mentioned topics, during my internship I began to develop some 
initial work as a clinical research coordinator. 
I had the opportunity to attend a study initiation visit training, from a multicenter clinical 
trial phase 3, in the area of Alzheimer's disease. In Portugal, it will only be conducted one 
arm of the study, and the Lenitudes MC&R will serve as a unit of support to centers in the 
northern part of the country, for diagnostic tests performed during the screening phase. Due 
to the PET-CT equipment, the unit is able to perform these tests that represent one of the 
steps to check that patients can be eligible to participate in the study. On this visit, the 
monitor of the Contract Research Organisation (CRO) involved went to the unit and 
provided training to the research team about their role on the study, the procedures which 
needed to be performed and their execution times.  I occupied the back-up function of the 
study coordinator. Whenever required, it is my job to establish the connection between the 
monitor, the clinic and the coordinators of the other research centers and perform 
scheduling of examinations of patients, depending on the prior order of the 
radiopharmaceutical. It was the first time that I had the opportunity to witness one such visit 
and was extremely interesting to see how these visits are performed in practice. 
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In addition, I still participated in the review of protocols and financial arrangements, 
accompanied and collaborated in the organization of documentation and in contact with all 
stakeholders involved, including the other members of the research team, monitors and 
coordinators of other centers. Despite of not being a function directly related to a clinical 
research coordinator, I also collaborate in the development sketch for the clinical research 
laboratory. This is a very important component of development of the R&D unit, since it is 
crucial to ensure the essential conditions for the proper functioning of clinical research 
activity according to good clinical practice defined by the ICH. Thus, the clinical research 
office should contain: 
!! Space for archives and for storage the kits (material, bottles for sampling); 
!! Workbench for transfer of patient samples; 
!! Centrifuge; 
!! Fridge/freezer; 
!! Work space. 
This was a challenging task since it allowed to go beyond my area of training and give my 
contribution to define the best working conditions for space where will be performed the 
clinical research activities. 
 
3.2.2! Quality management (SOPs) 
In addition to all the activities already described, I still had the opportunity to collaborate 
on some tasks related to the Quality Management. My main contribution was the 
development of SOPs, either under the Risk Management area or in more general fields. In 
addition to the development of the two SOPs related to the AE periodic monitoring reports 
mentioned above - "Collection of AE information in MOSAIQ Oncology Information System 
software" and "Development of AE periodic report" - I still had the function to develop a SOP 
regarding the processing of MD - "Circuit of delivery of MD for sterilization in out-sourcing". 
This procedure is also in accordance with standard of documentation control and presents 
a review periodicity of a year. This is also an important document, taking into consideration 
that the clinic was in a phase of establishing links with other companies to request services 
that could not be made centrally. In this sense, define how the DM are delivered to be 
sterilized in outsourcing is critical at this early stage. 
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4.!Training Sessions 
!! II Quality Journeys of CHEDV – 11th November 2015 
In this training there were addressed areas such as risk methods, hospital quality or 
quality indicators in the control of infection. The intervention of Prof. Dr. José Fragata about 
risk management was the one that most captivated my interest, both for the subject itself 
and by the unmistakable experience of Prof. Fragata in this area. The approach to improve 
procedures as opposed to solely focus on the errors of the people, promotes a culture of 
safety in which all can do more, better and safer. It was also very interesting the approach 
to the National Health Evaluation System (Sistema Nacional de Avaliação em Saúde – 
SINAS in portuguese) promoted by the Regulatory Authority of Health (Entidade 
Reguladora da Saúde – ERS in portuguese). This system arises as a result of concern for 
the right of citizens to access information regarding the quality of health services, promoting 
more informed decisions, and to continuously improve the quality of care. 
 
!! Course Drug Safety – 4th and 5th of March 2016 
As the main focus of my internship was the risk management area and 
pharmacovigilance, was of my interest conduct specific training in this area. In this sense, I 
was informed of the realization of the course "Drug Safety" promoted by UNAVE and 
immediately was interested in participate. In this course, were discussed topics such as 
quality healthcare and patient safety, the safety of the medication (medication errors, drug 
interactions, Look-Alike Sound-Alike (LASA) drugs, high alert drugs or high risk, therapeutic 
reconciliation) and pharmacovigilance and risk management. Given that the theoretical 
learning of this matter was entirely autonomous from the start of the internship, it was 
extremely important and enriching to conduct a training focused to my area of work. I had 
the opportunity to ask specific questions that appeared during the months of internship, I 
consolidated the knowledge that I acquired through literature and, above all, I strengthened 
my passion for this area. 
 
!! MOSAIQ Medical Oncology Training – 29th Feb to 3rd Mar; 16th, 17th Mar 2016 
As mentioned earlier, during my internship, Lenitudes MC&R was under development 
in several areas. One of them concerned the computer software for use in the oncology unit 
and day hospital. Thus, as at this point I had already developed the project on the main AE 
associated with the frequent chemotherapy regimens for the most common cancers, it was 
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suggested that I attend the training to understand how to integrate the work already 
performed. The software in question is called MOSAIQ Medical Oncology and was 
presented to the team in two stages: one week of basic training, where we were taught the 
main features of the system, and two days of advanced training in system configuration. 
The training was rewarding once I had the opportunity to realize how a clinical information 
system it is set up and, on the other hand, I could learn more about the existing functionality 
in the system for AE’s registration. 
 
!! Oncology Spring Meeting – 7th to 9th of April 2016 
The binding of Lenitudes and medical oncology area is assumed. For this reason, in 
April 2016 I was given the opportunity to participate in the national Oncology Spring Meeting 
that takes place every year in Evora. Among the wide lot of interesting conferences, I chose 
to watch those who most identified with my internship route, including lectures on "risk 
management" or "radiation toxicity management” (mucositis, for example). Besides the 
themes are very interesting and up to my expectations, it was very gratifying to have the 
opportunity to participate in an event of this magnitude and importance at the national level. 
 
!! Meeting about Clinical Trials, Health Cluster Portugal – 20th April 2016 
Although the R&D unit is not yet in full operation, the Lenitudes MC&R has always 
shown interest in embracing the area of clinical trials, as soon as the required conditions 
were met. In this context, I attended to the Meeting about Clinical Trials sponsored by the 
Health Cluster Portugal, in Braga. It was a highly enriching day, where were discussed 
extremely important issues for a center of clinical trials that want to start taking the first 
steps, such as the main characteristics of excellence centers and the major research 
opportunities. I believe that the presence of Lenitudes in this meeting was an added value 
to show the motivation and interest in this area and, on the other hand, to be able to have 
perception of the key factors for success in clinical trials. 
 
!! ICH Good Clinical Practice (GCP) – 21th April 2016 
Once I have performed some functions related to R&D department, where I collaborated 
in medical writing and project management it was necessary to perform a course of ICH 
GCP. Furthermore, as Lenitudes MC&R will participate in some clinical trials, particularly in 
carrying out the PETs needed, it is required that all members of the research team are 
trained on GCP.This online course, sponsored by Roche, provides a training focusing on 
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guidelines for researchers and research team regarding the conduct of clinical practice 
according to the standards of quality and ethics. 
 
!! Training in Radiation Protection and Safety – 16th May 2016 
Since the Lenitudes MC&R performs activities in the fields of nuclear medicine, imaging 
and radiation therapy, it is required to complete an annual training about radiation protection 
and safety, for all employees. In this session, held in Lenitudes facilities, were presented 
the various types of radiation that professionals of this unit could be exposed, the radiation 
sources, the protective measures we have to take and the dose limits set by law. 
 
!! International Day of Clinical Trials - Clinical Trials Investigator Initiative, 
PtCRIN – 25th May 2016 
As a way to commemorate the international day of the clinical trials, PtCRIN organized 
an event about clinical trials with investigator initiative, which I attended in Infarmed in 
Lisbon. The main objective of PtCRIN is the implementation, development and organization 
of the national infrastructure dedicated to clinical research, in line with the national health 
strategy and harmonized with European standards. In this sense, this session was 
developed in order to present some funding opportunities in Europe for clinical trials, 
highlighting the role of interventional studies with MD and the importance of the training of 
the research team in GCP.  
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5.!Discussion 
This section present the main obstacles and difficulties faced, as well as the most 
positive aspects of this journey. 
Even before starting my internship, I had the opportunity to meet the clinical director of 
Lenitudes MC&R where it was explained to me that the clinic was still in a start-up phase of 
its activity. This meant that the internship cannot be conducted only within R&D projects or 
clinical trials, since the structure was not prepared for it. Thus, I was proposed to develop a 
stand-alone project in another important area for the clinic: risk management and 
pharmacovigilance. This proposal came about because, in my first interview, I confessed 
that this was one of my elections area. I had my first contact with this area in the degree in 
Biomedical Sciences, in the curricular unit of clinical pharmacology, with a collaborator of 
the north pharmacovigilance unit. Soon there began to arise my interest in the safety area. 
To ensure that my interest in this field was true, I participated in a pharmacovigilance 
intensive course in the pharmacovigilance unit of Lisbon and ‘Vale do Tejo’ in 2014. If this 
training had already confirmed my desire to trace my journey in this direction, the module 
"Risk Management and Pharmacovigilance' of the master, held in Infarmed, came to end 
all doubts. I think the importance of ensuring the safety of drugs developed, as well as the 
safety of care, is an essential factor for the development of better health care. On the other 
hand, I think that my interest in this area is also due to my own personality. Of my nature, I 
am a person who prefers to have perception of the probability of risk or failure, in order to 
better prepare my interventions and reduce this possibility to a minimum. As such, I try to 
be proactive and identify what can go wrong before it happens. This is one of the 
fundamental pillars of risk management: identify and assess risk situations and try to avoid 
them. 
When I was proposed to perform my internship at Lenitudes MC&R, it was explained to 
me that this was an area that was missing to be develop and, therefore, I had the opportunity 
to begin to sketch from scratch. If on one hand I was delighted with the proposal, on the 
other hand I felt immediately a huge responsibility because I had no experience in the area, 
bringing in with me only the knowledge of previous training and appreciation for the area. 
The first three months of the internship were simultaneously the most difficult and the 
most challenging. Given that there was practically nothing done in this area in the unit, and 
there was no one trained in risk management, the first months demanded of me an 
exhaustive literature search. I tried to understand what is risk management, how the other 
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health units had organized its risk management systems, which methods used and how I 
could begin to trace the route of Lenitudes in this area. The tools provided by the Problem-
Based Learning method (PBL) during my academic training were essential to overcome 
these dififuldades. Thanks to PBL, I developed soft skills that were extremely important at 
this beginning of the internship: autonomy, research tools, critical thinking and problem-
solving skills. Thus, I faced this opportunity as a way to learn more about it and immersed 
myself in scientific articles about risk management, books and national and international 
standards that enabled me to acquire the knowledge necessary to start the project. The first 
major application of this research was the development of risk management manual of the 
Lenitudes units. I immediately realized the importance of this document, which assumed 
the clinic's position towards the safety of care, and its attitute against the risk. In this regard, 
I tried to compile the basics of risk management, introduce some theoretical concepts and 
suggested some approaches that, in my view, suited the Lenitudes strategy. The fact of 
having no expert colleague in this area in the unit and consequently I do not have anyone 
to consult and confirm my interpretations, conveyed me some insecurity in the beginning. 
However, over time I was having more confidence in the work performed. A crucial factor 
to consolidate the idea of being in the "good way" was the fact that the topics addressed in 
‘Drug Safety’ course (referred to in section 4) are the same as the study materials that 
served as the basis for my training on this theme. This course served as a validation of the 
proposals that I suggested in risk management manual were according to the ideas 
defended by the experts in the field. Once completed the manual, the strategy to follow was 
set. In a natural way, other documents were being drawn up, such as registration forms for 
the suggested procedures, incident reporting forms and some SOPs. 
One of the topics of work suggested at the beginning of my internship was to develop 
tools for monitoring AE associated with treatments and procedures performed in Lenitudes 
MC&R. After preparation of the risk management manual, I felt able to advance to this 
project. Thus, following the guiding principles of the manual, I suggested a reactive 
approach to monitor AE associated with chemotherapy, reported by health professionals.  
I did a bibliographical research seeking to identify the main AE recorded in the literature for 
the most common cancers and, in collaboration with the clinical director, I was building a 
model for the AE database. However, despite of the fact that the monitoring design was 
aimed initially to chemotherapy, at the beginning of the 2016 Lenitudes MC&R started with 
radiotherapy treatments, before the beginning of activity of the day hospital. Thus, taking 
the opportunity of receiving ten new patients every week, Prof. Francisco Pimentel 
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suggested to create a database with AE addressed to radiotherapy. This was a challenging 
activity since it was necessary to conduct further research because I had no knowledge of 
the most common reactions after treatment with radiation. So I went to this challenge in 
mind that I had much to learn, since my academic training practically does not focus on this 
area of treatment. For this, I had the help and cooperation of Dr. Fernando Costa, which 
proved to be always ready and available to "integrate me" in the radiotherapy universe. 
Once acquired the basic knowledge to support the monitoring of AE associated with 
radiotherapy, I began a new phase: the structuring and elaboration of periodic reports for 
monitoring AE. Throughout this process I came across some difficulties in extracting 
information from the computer software. The fact that the sections intended for AE 
registration are not defined at the beginning of the process meant that different health 
professionals (physicians and nurses) did not use the plataform in the same way – the 
radiation oncologist physicians registered in the "assessment" section, while nurses 
registered in the "nursing records" or in paper format). Despite it seems a small detail, the 
fact that the registration method is not uniform meant that sometimes the AE record, made 
by different professionals, were not consistent for the same patient. In addition, the use of 
different rating scales for the same AE became difficult to analyze the registered information 
regarding to the comparison between records. This was one of the main difficulties that I 
felt in this phase of the internship. The lack of adequacy of the software tool, namely the 
absence of crucial fields such as the start and end date of the AE, was a limiting factor for 
the work that I was doing. However, I identified that it was possible to overcome some of 
the obstacles just giving adequate information to professionals. So I got in touch with 
nursing team in order to standardize the scale and the severity of the AE used in the 
registers and this problem has been resolved. On the other hand, the construction process 
of the first report also required a lot of time and dedication, with several interventions needed 
until it was achieved the ideal structure. This writing work and readjustment was done in 
collaboration with Dr. Fernando Costa, who was giving me indications of what to improve in 
each version of the document. Once established the definitive format, all subsequent 
reports were conducted without difficulty. In order to accomplished this, it was also essential 
the automation of the excel database, so that the statistical data analysis and preparation 
of graphs and tables were made quickly and without requiring user intervention. After many 
hours dedicated to this work, I think it was quite interesting to be able to use the computer 
skills acquired throughout my academic career in clinical practice. I can say that the whole 
process concerning the preparation of periodic reports, with the constant monitoring of 
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patient records to extract all the reported AE, interpretation and evaluation of causality, were 
the most challenging and rewarding tasks throughout this internship. The fact that there was 
not anything previously defined for this purpose demanded greater responsibility, not only 
in structuring the preparation method and reporting format, but also in how the results are 
disseminated among the staff members and how they saw the importance of risk 
management in a clinical unit. 
The fact that the unit is still in the development stage allowed me to have contact with 
different areas and work on various tasks. Although during the master I have done several 
works where I put my skills of medical writing in practice, I had some fear that in the real 
world I could not meet the expectations outlined by my superiors. I think this was one of the 
positive aspects of my internship, because I had the opportunity to prepare several 
documents that have consolidated my writing skills, whether they were minutes of meetings 
of research projects, an editorial in a journal, or simply professionals emails. On the other 
hand, collaboration in project management was also very challenging because I had no 
experience in the area. I have acquired the basic knowledge to manage a project, reconcile 
the various stakeholders and manage the tasks to perform. 
I think that I have achieved all objectives previously defined concerning the master’s 
degree and my host organization aims. I contributed to the successful monitoring of AE 
associated with radiotherapy, occurred during four moths in Lenitudes MC&R. This task not 
only permitted, month to month, to identify what could be improved, but also allowed the 
unit to had a record of the AE that occurred since the first radiotherapy treatment. In 
prospective terms, this information can be very valuable to demonstrate, for example, a 
minor occurrence rate of AE and the evident quality of services, resulting in increased 
satisfaction by patients when choosing the unit where they want to perform their treatments. 
On the other hand, I have a deep understanding of risk management systems and 
knowledge on some methods adopted by different entities.  
On a personal level, I have developed some soft skills that are essential to the 
professional world, such as the sense responsibility and autonomy, organisation, the time 
management, attention to details, communication skills and adaptation to clinical 
environment. 
In summary, I can emphasise that having to build this project in an autonomous way, 
just based on the learning acquired along bachelor and master course, and knowledge 
obtained through the available literature, made this phase of my academic career most 
challenging and demanding. I take with me nine months of excellent learning, where I was 
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able of understanding better my strengths and difficulties. This was one of the most 
enriching experiences of my academic journey and I will continue to learn more and more, 
take on new challenges and grow professionally and personally. 
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6.!Conclusion  
The assessment of patient safety and health care provided has been the subject of 
several recommendations over the recent times. The main objective is to promote changes 
to achieve a higher safety culture, which results in greater patient satisfactio. Thus, have 
knowledge of incidents occurring in the various medical facilities, identifying the frequency, 
their causes and impact, is the first step towards this improvement. Taking into account the 
impact that the AE have in morbidity of patients, it is easy to see that monitoring them is 
essential for health organizations to seek opportunities for improvement in the quality of 
health care they provide. 
I am pleased for having had the opportunity to do my internship in Lenitudes MC&R and 
to have developed a project in this area. It was a unique experience that has challenged my 
autonomy, responsibility, organization and the knowledge acquired during academic 
education related to risk management, pharmacovigilance and R&D. This was, certainly, 
one of the most enriching years of my academic career and allowed me to grow and become 
a more competent professional. In addition, this stage helped me to better understand my 
interests, my strengths and weaknesses and my profile as a professional in the clinical 
research area. I also realized that the ability to research, allied to dedication and 
cooperation with experts are essential tools for achieving success in any task performed. 
Therefore, I can conclude that I finish my second year of the Master's course in 
Pharmaceutical Biomedicine with the feeling of satisfaction of having reached the 
predefined objectives and developed strong soft skills. Now, I'm ready to do and learn more, 
enjoy all given opportunities and face the world of work. 
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Annexes 
 
Annex I - Risk Management Manual (first page and some sections presented in this 
document) 
 
 
Nome do documento: Gestão de Risco 
 
 
Tipo de documento: 
Manual 
Nº/Versão: Data da 1ª versão:  
Elaboração em: 
18/02/2016  
Revisão em:  Aprovação em: Revogação em:  
Por: Ana Rita Marques 
 
Por:  Por:  Por:  
 
 
 
 
   
MANUAL 
DE  
GESTÃO DE RISCO 
 
 
 Documento truncado com informação confidencial. 
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A importância da Gestão de Risco para as Unidades de Saúde Lenitudes 
A gestão de risco diz respeito a um conjunto de medidas estabelecidas para aumentar 
a segurança e, assim, a qualidade de prestação dos cuidados de saúde. A Lenitudes atribui 
elevada importância aos processos de gestão de qualidade e, por conseguinte, às 
atividades de gestão de risco. Desta forma, através da identificação prospetiva das 
circunstâncias que colocam os doentes em risco e da atuação na prevenção e controlo 
desses mesmos riscos, é possível atender a um grau de maior exigência e procura por 
cuidados com níveis de qualidade mais elevados.   
É indiscutível que os símbolos de garantia, acreditação e/ou certificação são essenciais 
para que uma unidade de saúde consiga conquistar o mercado nacional e se expandir para 
mercados internacionais. A gestão de risco pode auxiliar neste âmbito, dado que a 
ocorrência de eventos adversos graves nas instituições sugere às autoridades externas 
(ainda que não prove), que existe uma falha nos esforços para salvaguardar a segurança 
do doente. Desta forma, a implementação de sistemas de relato de incidentes, enquanto 
ferramenta de gestão do risco, é fortemente recomendada em todas as instituições que se 
submetem a processos de acreditação externa, seja através da Joint Comission (JC) ou da 
Caspe Healthcare Knowledge Systems (CHKS). 
A melhoria da segurança da prestação de cuidados evita perdas importantíssimas não 
só em vidas humanas, mas também em custos económicos para a própria empresa 
(readmissões hospitalares, medicação para tratamento de eventos adversos, entre outros). 
Para além disto, o enfoque nesta área pode traduzir-se num aumento da confiança nas 
unidades de saúde e nos seus profissionais, por parte dos utentes, e também no aumento 
da motivação dos próprios colaboradores da empresa, contribuindo para um melhor 
desempenho. 
Torna-se, assim, fundamental encarar a gestão de risco e a segurança do doente como 
peças fundamentais na concretização do conceito de “unidade de referência”, ao procurar 
melhorar a qualidade na saúde e prestar cuidados de excelência. 
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Annex II - Standard record for the process of RCA 
 
FORMULÁRIO DE REGISTO – ANÁLISE DAS CAUSAS RAIZ 
Este ficheiro deve incluir toda a informação considerada necessária que tenha sido adquirida 
através do processo de Análise de Causas Raiz (ACR). 
Breve descrição do incidente/evento clínico 
 
Data do incidente ____/____ /____  (dd/mm/aa) Hora do incidente 
___:___  
(Horas:Minutos) 
Nome do notificador  Serviço  
Causas Proximais 
 
 
 
 
 
 
Fatores Contribuintes 
I – Fatores do pessoal, comunicação 
II – Fatores do pessoal, formação 
III – Fatores do pessoal, recursos/carga de trabalho 
IV – Fatores do trabalho ou do ambiente, ambiente físico e equipamentos 
V – Fatores organizacionais ou do serviço, protocolos e procedimentos 
VI – Barreiras 
Recomendações de medidas a tomar para evitar a recorrência do incidente 
 
 
 
 
 
 
Notificado por: _______________________  Data: ____/____ /____          (dd/mm/aa) 
 
Assinatura: __________________________  
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Annex III - Standard record for the process of the identification and assessment of risk 
 
FORMULÁRIO DE REGISTO – IDENTIFICAÇÃO E AVALIAÇÃO DO RISCO 
Este ficheiro deve incluir toda a informação considerada necessária que tenha sido adquirida pelo 
processo de identificação e avaliação de risco, de forma a documentar o risco em análise. 
 
Data: ____/____ /____  (dd/mm/aa) 
Designação do Procedimento/Dispositivo Médico: _________________________________ 
Classe de Risco de Equipamento (se aplicável):____________________________________ 
Perigos identificados: 
____________________________________________________________________________
____________________________________________________________________________ 
 
 
Risco atribuído: (C x P) = ___ x ___ = ___ 
Risco baixo Risco moderado       Risco alto Risco extremo 
Risco extremo Ocorrência quase certa, pelo menos uma vez, nos próximos três meses. 
Necessárias medidas corretivas imediatas.  
Revisão semanal 
Risco alto Ocorrência provável, pelo menos uma vez, nos próximos 4-12 meses. 
Necessária atenção especial na gestão do caso. 
Revisão mensal 
Risco moderado Ocorrência provável no período de 1-2 anos. 
Responsabilidade da gestão deve ser 
especificada. 
Revisão anual 
Risco baixo Ocorrência possível em alguma altura no período de 2+ anos. 
Procedimentos de rotina. 
Revisão se os procedimentos sofrerem 
alterações. 
 
Medidas de Controlo de Risco: 
____________________________________________________________________________
____________________________________________________________________________ 
Notificado por: _______________________   Data: ____/____ /____ 
        (dd/mm/aa) 
Assinatura: ________________________ 
Consequências 
(C) 
Probabilidade (P)  
1 - 3 Risco baixo 
4 - 6 Risco moderado 
8 - 12 Risco alto 
15-25 Risco extremo 
 
1 2 3 4 5 
Raro Improvável Possível Provável Quase certo 
5 Catastróficas 5 10 15 20 25 
4 Maiores 4 8 12 16 20 
3 Moderadas 3 6 9 12 15 
2 Menores 2 4 6 8 10 
1 Insignificante 1 2 3 4 5 
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Annex IV - ADR reporting form 
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Annex V - SOP for "Collection of AE’s information on MOSAIQ® Oncology 
Information System software" 
 
1.! Âmbito: 
-! Esta instrução de trabalho aplica-se à Lenitudes. 
-! A equipa do grupo de apoio técnico de Gestão de Risco da Lenitudes pretende proceder à 
elaboração de relatórios periódicos de monitorização dos Eventos Adversos (EA) registados 
pelos profissionais de saúde, associados à radioterapia. 
 
2.! Objetivos: 
-! Definir a estrutura e processo de elaboração/divulgação do relatório periódico de monitorização 
de EA. 
 
3.! Campo de Aplicação/ Destinatários: 
-! Grupo de apoio técnico de Gestão de Risco. 
 
4.! Referências:  
-! Não aplicável. 
 
5.! Definições 
-! Não aplicável. 
 
6.! Responsabilidades: 
-! Equipa do grupo de apoio técnico de Gestão de Risco. 
 
7.! Descrição: 
7.1.!Elaboração do relatório 
-! O relatório periódico de monitorização de EA é elaborado pela equipa do grupo de apoio técnico 
de Gestão de Risco. 
 
-! O principal objetivo do relatório é permitir avaliar a toxicidade dos tratamentos de radioterapia, 
prestados na Lenitudes Medical Center & Research.  
 
-! A informação para análise é recolhida conforme se encontra descrito no procedimento interno 
normalizado “Recolha informação sobre Eventos Adversos do software MOSAIQ® Oncology 
Information System”. 
 
-! A análise estatística dos dados apresentados é efetuada através da ferramenta Excel. 
 
 
Nome do documento: Elaboração do Relatório 
Periódico de Monitorização de Eventos Adversos 
 
Tipo de documento: 
Procedimento 
Nº/Versão: 1 Data da 1ª versão:  
25-02-2016 
Elaboração em: 25-02-2016 Revisão em: Aprovação em: Revogação em:  
Por:     Ana Rita Marques Por:  Por:  Por:  
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7.2.!Estrutura do relatório 
-! Cabeçalho: indicação do mês e do ano em que os EA foram recolhidos; 
-! Contextualização:  
a.! Número de doentes a serem seguidos em radioncologia, na Lenitudes Medical Center 
& Research;  
b.! Número de doentes a realizar sessões de radioterapia; 
c.! Média de idades dos doentes (em anos); 
d.! Número de doentes por diferentes neoplasias. 
-!  Análise estatística dos resultados: 
a.! Número de EA notificados; 
b.! Tipos de EA notificados; 
c.! Gravidade de EA notificados; 
d.! Distribuição dos EA por patologia; 
e.! Distribuição dos EA por estadio da neoplasia; 
f.! Taxa de doentes com EA vs. doentes sem manifestação de EA. 
-! Conclusões: avaliação global dos dados – comparação com o que está previsto na literatura 
para casos semelhantes; apreciação sobre as medidas tomadas e sugestões de medidas a 
adotar em situações futuras. 
-! Quadros resumo (mensal e semestral) com informação sintetizada sobre os doentes que 
concluíram tratamento em cada mês, quantos manifestaram EA e de que tipo. 
NOTA: O primeiro relatório (referente ao mês de Fevereiro de 2016) inclui uma secção introdutória ao tema dos EA 
associados à radiação. Pretende-se, assim, contextualizar os dados que são analisados, de forma a avaliar a 
causalidade dos efeitos adversos de forma sustentada.  
 
7.3.!Política de divulgação do relatório 
-! O relatório tem uma periocidade mensal, incluindo os registos inseridos na base de dados entre 
o primeiro e o último dia de cada mês. 
-! De forma a permitir que os dados registados na base de dados nos últimos dias de cada mês 
sejam incluídos na análise, o relatório é divulgado até ao dia 15 do mês seguinte. 
-! O relatório deve ser divulgado junto de todos os profissionais de saúde da Lenitudes Medical 
Center & Research, através de correio eletrónico (e-mail). 
 
8.! Periodicidade de revisão: 
-! A revisão desde documento apresenta uma periodicidade anual, caso não exista nenhuma 
ocorrência que justifique a sua antecedência.  
 
9.! Registo de Revisões: N/A 1ª Versão do documento.  
  
10.!Anexos: Não aplicável. 
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Annex VI - Periodic report monitoring AE in radiotherapy (March 2016) 
 
 
Nome do documento: Relatório periódico de monitorização 
de eventos adversos em radioterapia 
 
Tipo de documento: Relatório Nº/Versão: 1 Data 1ª versão: 
14/04/2016 
Elaboração em: 
14/04/2016 
Revisão em: 15/04/2016 Aprovação em: 15/04/2016 Revogação em:  
Por:   Ana Rita Marques 
 
Por: Dr. Fernando Costa  
(Médico Radioncologista) 
Por: Prof. Francisco 
Pimentel (Diretor Clínico) 
Por:  
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Documento truncado com informação confidencial.  
 
O presente relatório apresenta a seguinte estrutura: contextualização; distribuição 
dos doentes por tipo de neoplasia e tipo de técnica de radioterapia utilizada; análise 
dos registos de eventos adversos (geral e por área anatómica); conclusão; quadro-
resumo mensal e semestral. 
